<SEC-DOCUMENT>0001213900-22-081927.txt : 20221222
<SEC-HEADER>0001213900-22-081927.hdr.sgml : 20221222
<ACCEPTANCE-DATETIME>20221222064345
ACCESSION NUMBER:		0001213900-22-081927
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20221222
DATE AS OF CHANGE:		20221222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256830
		FILM NUMBER:		221479695

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>f424b51222_neuroone.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD><TITLE></TITLE></HEAD>
<BODY STYLE="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><DIV STYLE="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:right;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Filed Pursuant to Rule&#x00a0;424(b)(5)<BR>Registration No.&#x00a0;333</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-256830</FONT></FONT></P>
		</DIV>
	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Prospectus Supplement<BR>(to Prospectus dated June&#x00a0;14, 2021)</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">$1</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">4</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">,500,000</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="tneuro_logo.jpg" STYLE="width:399.36px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;">NeuroOne Medical Technologies Corporation</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">Common Stock</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We have entered into a Capital on Demand&#x2122; Sales Agreement, or sales agreement, with JonesTrading Institutional Services LLC, or JonesTrading, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $14,500,000 from time to time through or to JonesTrading (the &#x201c;Agent&#x201d;) acting as sales agent or principal, at our discretion.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &#x201c;at the market offerings&#x201d; as defined in Rule&#x00a0;415 promulgated under the Securities Act&#x00a0;of&#x00a0;1933, as amended, or the Securities Act. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">We will pay the Agent commissions for its services in acting as agent in the sale of our common stock. The Agent will be entitled to compensation at a commission rate equal to 3.0% of the aggregate gross sales price of the shares sold. In connection with the sale of our common stock on our behalf, the Agent will be deemed to be an &#x201c;underwriter&#x201d; within the meaning of the Securities Act and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &#x201c;NMTC.&#x201d; The last reported sales price of our shares of common stock on December&#x00a0;20, 2022 was $2.05 per share.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The aggregate market value of our outstanding common stock held by non<FONT CLASS="nobreak">-affiliates</FONT>, or the public float, as of the date hereof pursuant to General Instruction&#x00a0;I.B.6. of Form&#x00a0;S<FONT CLASS="nobreak">-3</FONT>, was approximately $43.6&#x00a0;million, which was calculated based upon 15,444,178<FONT CLASS="nobreak"> </FONT>shares of our outstanding common stock held by non<FONT CLASS="nobreak">-affiliates</FONT> at a price of $2.82 per share, the closing price of our common stock on December&#x00a0;9, 2022. Pursuant to General Instruction&#x00a0;I.B.6 of Form&#x00a0;S<FONT CLASS="nobreak">-3</FONT>, in no event will we sell our securities in a public primary offering with a value exceeding more than one<FONT CLASS="nobreak">-third</FONT> of our public float in any 12<FONT CLASS="nobreak">-month</FONT> period so long as our public float remains below $75&#x00a0;million. We have not offered any securities pursuant to General Instruction&#x00a0;I.B.6 of Form&#x00a0;S<FONT CLASS="nobreak">-3</FONT> during the 12 calendar&#x00a0;months prior to and including the date of this prospectus supplement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Investing in our securities involves a high degree of risk. Please read carefully the information contained in or incorporated by reference under the heading &#x201c;Risk Factors&#x201d; beginning on page </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">S</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-4</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. A</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ny representation to the contrary is a criminal offense.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="tjonestrading_logo.jpg" STYLE="width:181.76px;max-width:100%;"></FONT></P>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The date of this prospectus supplement is December&#x00a0;21, 2022</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1_TOC" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><A NAME="TOC001"></A>TABLE OF CONTENTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Page</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Prospectus Supplement</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T26">About This Prospectus Supplement</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-ii</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99501">Summary</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99502">Overview</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99503">Company Information</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99504">The Offering</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99505">Risk Factors</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99506">Special Note&#x00a0;Regarding Forward-Looking Statements</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-6</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99507">Use of Proceeds</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-8</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99508">Dilution</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-9</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99509">Plan of Distribution</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-10</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99510">Legal Matters</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99511">Experts</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99512">Where You Can Find More Information</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99513">Incorporation by Reference</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">S-12</P>
					</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Page</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Prospectus</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99601">About This Prospectus</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ii</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99602">Summary</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99603">Risk Factors</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">6</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99604">Special Note&#x00a0;Regarding Forward-Looking Statements</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">7</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99605">Use of Proceeds</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">8</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99606">Desciription of Common Stock</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">9</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99607">Description of Preferred Stock</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99608">Description of Debt Securities</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">13</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99609">Description of Warants</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">19</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99610">Legal Ownership of Securities</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">21</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99611">Plan of Distribution</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">24</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99612">Legal Matters</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99613">Experts</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99614">Where You Can Find More Information</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99615">Incorporation of Certain Information By Reference</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">27</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-i</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T26"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus supplement and the accompanying prospectus relate to the offering of our common stock. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement entitled &#x201c;Where You Can Find More Information&#x201d; and &#x201c;Incorporation by Reference.&#x201d; These documents contain important information that you should consider when making your investment decision.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This document is divided in two parts. The first part is this prospectus supplement, which describes the specific terms of the offering of the common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference into the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to the combined document consisting of this prospectus supplement and the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference into the accompanying prospectus that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are responsible for the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and the Agent has not, authorized any other person to provide you with different information, and neither we nor the Agent take any responsibility for any other information that others may give you.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are not, and the Agent is not, making an offer to sell or soliciting an offer to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In this prospectus, the terms &#x201c;NeuroOne,&#x201d; &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to NeuroOne Medical Technologies Corporation, and its subsidiaries collectively, unless the context otherwise requires.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-ii</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99501"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SUMMARY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">This summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should read this entire prospectus supplement and the accompanying prospectus carefully, including the &#x201c;Risk Factors&#x201d; section contained in this prospectus supplement, our financial statements and the related notes thereto and the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99502"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are developing our cortical sheet and depth electrode technology to provide solutions for diagnosis through cEEG recording and sEEG recording and treatment through spinal cord stimulation, brain stimulation and ablation, all in one product. A cEEG is a continuous recording of the electrical activity of the brain that identifies the location of irregular brain activity, which information is required for proper treatment. cEEG recording involves an invasive surgical procedure, referred to as a craniotomy. sEEG involves a less invasive procedure whereby doctors place electrodes in targeted brain areas by drilling small holes through the skull. Both methods of seizure diagnosis are used to identify areas of the brain where epileptic seizures originate in order to precisely locate the seizure source for therapeutic treatment if possible.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Deep Brain Stimulation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deep brain stimulation, or DBS, therapies involve activating or inhibiting the brain with electricity that can be given directly by electrodes on the surface or implanted deeper in the brain via depth electrodes. Introduced in 1987, this procedure involves implanting a power source referred to as a neurostimulator, which sends electrical impulses through implanted depth electrodes, to specific targets in the brain for the treatment of disorders such as Parkinson&#x2019;s disease, essential tremor, dystonia, and chronic pain. Alzheimer&#x2019;s is another indication evaluating the effects of DBS.&#x00a0;Unlike ablative technologies, the effects of DBS are reversible.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">RF Ablation</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">RF ablation is a procedure that uses radiofrequency under the electrode contacts that is directed to the site of the brain tissue that is targeted for removal. The process involves delivering energy to the contacts, thereby heating them and destroying the brain tissue. The ablation does not remove the tissue. Rather, it is left in place and typically scar tissue forms in the place where the ablation occurs. This procedure is also known as brain lesioning as it causes irreversible lesions.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Failed Back Surgery Syndrome</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failed back surgery syndrome (&#x201c;FBSS&#x201d;) is a condition that produces chronic lower back/leg pain due to one or more failed back surgeries. Typically, it is related to patients that suffer with pain after surgery of the lumbar spine for degenerative disc disease. Re<FONT CLASS="nobreak">-operations</FONT> are usually not recommended for these patients due to low success rates. These patients experience greater levels of pain, a lower quality of life, varying levels of disability and higher rate of unemployment. Spinal cord stimulation works by placing an electrodes(s)&#x00a0;in a targeted area of the spine and then connected to an implantable pulse generator that sends electrical stimulation to the electrode to block the pain signals from reaching the brain.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Regulatory Developments</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our cortical sheet electrode and depth electrode technology have been tested over the&#x00a0;years by both WARF, the owners of our licensed patents, and Mayo Clinic located in Rochester, Minnesota, in both pre<FONT CLASS="nobreak">-clinical</FONT> models as well as through an IRB approval at Mayo Clinic for clinical research. Regarding our ablation electrode, the Cleveland Clinic has performed testing in bench top models and pre<FONT CLASS="nobreak">-clinical</FONT> (or animal testing) modes. These pre<FONT CLASS="nobreak">-clinical</FONT> tests have demonstrated that the technology is capable of recording, ablation and acute stimulation.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We received FDA clearance for our Evo cortical technology in November&#x00a0;2019 for recording, monitoring, and stimulating brain tissue for up to 30&#x00a0;days, in October&#x00a0;2022 we received FDA clearance to market our Evo sEEG electrode technology for temporary (less than 30&#x00a0;days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. We believe that the global diagnostic electrode addressable market is over $100&#x00a0;million.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99503"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Company Information</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our principal executive offices are located at 7599 Anagram Dr., Eden Prairie, MN&#x00a0;55344, and our telephone number is&#x00a0;952<FONT CLASS="nobreak">-426-1383</FONT>. We maintain a website at <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.n1mtc.com</FONT>, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the SEC, will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC.&#x00a0;Information contained on, or accessible through, our website does not constitute a part of this prospectus or our other filings with the SEC, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase shares of our Common Stock.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99504"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The Offering</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">

						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Common stock offered by us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#x00a0;<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Shares of our common stock having an aggregate offering price of up to $14,500,000.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Manner of offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be &#x201c;at the market offerings&#x201d; as defined in Rule&#x00a0;415 promulgated under the Securities Act. See &#x201c;Plan of Distribution&#x201d; on page S<FONT CLASS="nobreak">-10</FONT> of this prospectus supplement for a more complete description of the manner of offering.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Use of proceeds</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We expect to use the net proceeds from this offering for general corporate purposes. Please see &#x201c;Use of Proceeds&#x201d; on page S<FONT CLASS="nobreak">-8</FONT>.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Risk factors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading &#x201c;Risk Factors&#x201d; beginning on page S<FONT CLASS="nobreak">-4</FONT> of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-top:10pt;vertical-align:top;width: 39.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Nasdaq Capital Market symbol</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">NMTC</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99505"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISK FACTORS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">An investment in our securities involves risks. We urge you to consider carefully the risks described below, and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision, including those risks and uncertainties discussed under the heading &#x201c;Risk Factors&#x201d; contained in our Annual Report on Form&#x00a0;10</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-K</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> for the year ended September&#x00a0;30, 2022, which are incorporated by reference in this prospectus supplement and which may be amended, supplemented or superseded from time to time by other reports that we subsequently file with the SEC.&#x00a0;Additional risks, including those that relate to any particular securities we offer, may be included in a future prospectus supplement or free writing prospectus that we authorize from time to time, or that are incorporated by reference into this prospectus supplement or the accompanying prospectus in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &#x201c;Special Note&#x00a0;Regarding </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Statements.&#x201d;</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to this Offering</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Sales of our common stock in this offering, or the perception that such sales may occur, could cause the market price of our common stock to fall.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may issue and sell shares of our common stock for aggregate gross proceeds of up to $14,500,000 from time to time in connection with this offering. The issuance and sale from time to time of these new shares of common stock, or our ability to issue these new shares of common stock in this offering, could have the effect of depressing the market price of our common stock.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our management will have broad discretion as to the use of the net proceeds from any offering by us and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, if any, return for us.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">You may experience immediate and substantial dilution in the book value per share of the common stock you purchase in the offering.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The public offering price per share in this offering may exceed the pro forma as adjusted net tangible&#x00a0;book value per share of our common stock after giving effect to this offering. Assuming that an aggregate of 7,073,171<FONT CLASS="nobreak"> </FONT>shares of our common stock are sold at a price of $2.05 per share, the last reported sale price of our common stock on Nasdaq on December&#x00a0;20, 2022, for aggregate gross proceeds of up to approximately $14,500,000, and after deducting commissions and estimated offering expenses payable by us, you will experience immediate dilution of $1.05 per share, representing the difference between our pro forma as adjusted net tangible book value per share as of 1.00, after giving effect to this offering. See the section below entitled &#x201c;Dilution&#x201d; for a more detailed illustration of the dilution you would incur if you participate in this offering.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The actual number of shares we will issue under the sales agreement, at any one time or in total, is uncertain.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Agent at any time throughout the term of the sales agreement. The number of shares that are sold by the Agent after delivering a placement notice will fluctuate based on the market price of the common shares during the sales period and limits we may set with the Agent. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The common stock offered hereby will be sold in &#x201c;at the market offerings&#x201d;, and investors who buy shares at different times will likely pay different prices.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Investors who purchase shares in this offering at different times will likely pay different prices, and, therefore, may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We do not intend to pay dividends for the foreseeable future.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While we have in the past declared and paid cash dividends on our common stock, we do not currently plan to pay any cash dividends on our common stock for the foreseeable future. As a result, only appreciation of the price of our common stock, if any, will provide a return to our stockholders with respect to our common stock.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-5</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99506"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FORWARD-LOOKING</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> STATEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus supplement, the accompanying prospectus and the documents incorporated herein by reference contain forward<FONT CLASS="nobreak">-looking</FONT> statements that involve substantial risks and uncertainties. In some cases, you can identify forward<FONT CLASS="nobreak">-looking</FONT> statements by the words &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan,&#x201d; &#x201c;objective,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;target,&#x201d; &#x201c;seek,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue&#x201d; and &#x201c;ongoing,&#x201d; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward<FONT CLASS="nobreak">-looking</FONT> statements. Although we believe that we have a reasonable basis for each forward<FONT CLASS="nobreak">-looking</FONT> statement contained in this prospectus supplement, the accompanying prospectus and the documents incorporated herein by reference, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward<FONT CLASS="nobreak">-looking</FONT> statements include statements about:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our plans to develop and commercialize our cortical strip, grid and depth electrode technology;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the timing of and our ability to obtain and maintain regulatory approval of our cortical strip, grid and depth electrode technology;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to obtain and maintain regulatory clearance for our RF ablation system;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to successfully commercialize our technology in the United&#x00a0;States;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to achieve or sustain profitability;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to raise additional capital and to fund our operations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the availability of additional capital on acceptable terms or at all as or when needed;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the clinical utility of our cortical strip, grid and depth electrode including technology under development;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to develop our cortical strip, grid and depth electrode technology with the benefits we hope to offer as compared to existing technology, or at all;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the results of our development and distribution relationship with Zimmer, Inc.;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the performance, productivity, reliability and regulatory compliance of our third party manufacturers of our cortical strip, grid electrode and depth electrode technology;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to develop future generations of our cortical strip, grid and depth electrode technology;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our future development priorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the impact of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic on our business;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to obtain reimbursement coverage for our cortical strip, grid and depth electrode technology;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our expectations about the willingness of healthcare providers to recommend our cortical strip, grid and depth electrode technology to people with epilepsy, Parkinson&#x2019;s disease, essential tremors, and other brain related disorders;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our future commercialization, marketing and manufacturing capabilities and strategy;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to comply with applicable regulatory requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to maintain our intellectual property position;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our estimates regarding the size of, and future growth in, the market for our technology under development; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our estimates regarding our future expenses and needs for additional financing.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-6</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Forward<FONT CLASS="nobreak">-looking</FONT> statements are based on management&#x2019;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#x2019;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. You should refer to the &#x201c;Risk Factors&#x201d; section of this prospectus supplement, the accompanying prospectus and the documents incorporated herein by reference for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward<FONT CLASS="nobreak">-looking</FONT> statements. As a result of these factors, we cannot assure you that the forward<FONT CLASS="nobreak">-looking</FONT> statements will prove to be accurate. Furthermore, if our forward<FONT CLASS="nobreak">-looking</FONT> statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward<FONT CLASS="nobreak">-looking</FONT> statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These forward<FONT CLASS="nobreak">-looking</FONT> statements speak only as of the date of this prospectus supplement. Except as required by law, we assume no obligation to update or revise these forward<FONT CLASS="nobreak">-looking</FONT> statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) after the date of this prospectus supplement.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-7</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99507"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">USE OF PROCEEDS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may issue and sell shares of our common stock having aggregate sale proceeds of up to $14,500,000 from time to time. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with the Agent as a source of financing. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We currently intend to use any net proceeds from the sale of securities under this prospectus primarily to fund general corporate purposes.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The amount and timing of our use of the net proceeds from any offerings hereunder will depend on a number of factors, including the factors described under &#x201c;Risk Factors&#x201d; in this prospectus supplement and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending the application of the net proceeds, we may invest the proceeds in short<FONT CLASS="nobreak">-term</FONT>, interest<FONT CLASS="nobreak">-bearing</FONT> instruments or other investment<FONT CLASS="nobreak">-grade</FONT> securities.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-8</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99508"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DILUTION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you purchase shares of our common stock in this offering, you will experience dilution to the extent of the difference between the public offering price per share and the pro forma as adjusted net tangible book value per share after giving effect to this offering. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding shares of our common stock. Dilution represents the difference between the public offering price per share paid by purchasers in this offering and the pro forma as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. Our net tangible book value as of September&#x00a0;30, 2022 was approximately $9.3&#x00a0;million, or $0.57 per share.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After giving effect to the assumed sale in this offering of $14,500,000 of our common stock, at an assumed public offering price of $2.05 per share, the last reported sale price of our common stock on Nasdaq on December&#x00a0;20, 2022, and after deducting the commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&#x00a0;30, 2022 would have been $23.3&#x00a0;million, or $1.00 per share of common stock. This represents an immediate increase in the pro forma as adjusted net tangible book value of $0.43 per share to our existing stockholders and an immediate dilution in net tangible book value of $1.05 per share to new investors. The following table illustrates this per share dilution:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assumed public offering price per share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.05</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net tangible book value per share as of September&#x00a0;30, 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.57</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increase in pro forma net tangible book value per share attributable to this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.43</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma as adjusted net tangible book value per share after giving effect to this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.00</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 73.53%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dilution per share to new investors participating in this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.05</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The above table and discussion is based on 16,216,540<FONT CLASS="nobreak"> </FONT>shares of common stock outstanding as of September&#x00a0;30, 2022 and exclude the following, all:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>1,239,915<FONT CLASS="nobreak"> </FONT>shares of common stock issuable upon the exercise of outstanding stock options with a weighted<FONT CLASS="nobreak">-average</FONT> exercise price of $5.40 per share;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>7,103,444<FONT CLASS="nobreak"> </FONT>shares of common stock issuable upon the exercise of outstanding warrants with a weighted<FONT CLASS="nobreak">-average</FONT> exercise price of $5.98 per share;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>414,430 unvested restricted stock awards; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>1,703,872<FONT CLASS="nobreak"> </FONT>shares available for future issuance under the Company&#x2019;s 2017 Equity Incentive Plan and 2021 Inducement Plan.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-9</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99509"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PLAN OF DISTRIBUTION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have entered into a Capital on Demand&#x2122; Sales Agreement, or sales agreement, with JonesTrading, under which we may issue and sell shares of our common stock from time to time through or to the Agent acting as our sales agent or principal. Sales of our common stock, if any, under this prospectus may be made in sales deemed to be &#x201c;at the market offerings&#x201d; as defined in Rule&#x00a0;415 promulgated under the Securities Act. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock from time to time having an aggregate gross sales price of up to $14,500,000 pursuant to this prospectus.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each time we wish to issue and sell common stock, we will notify the Agent of the number or dollar value of shares to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed the Agent, unless the Agent declines to accept the terms of the notice, the Agent has agreed, subject to the terms and conditions of the sales agreement, to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified in the notice. We may instruct the Agent not to sell shares of common stock if the sales cannot be effected at or above the price designated by us in any such instruction. We or the Agent may suspend the offering of shares of common stock being made through the Agent under the sales agreement upon proper notice to the other party.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will pay the Agent commissions for its services in acting as agent in the sale of our common stock. The Agent will be entitled to compensation at a commission rate equal to 3.0% of the aggregate gross sales price of the shares sold. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse the Agent for certain specified expenses, including the fees and disbursements of its legal counsel in an amount not to exceed $50,000, and ongoing diligence expenses in an amount not to exceed $10,000 in the aggregate per calendar year, as provided in the sales agreement. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to the Agent under the terms of the sales agreement, will be approximately $100,000.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Settlement for sales of common stock will occur on the second business&#x00a0;day following the date on which any sales are made, or on some other date that is agreed upon by us and the Agent in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of our transfer agent, Securities Transfer Corporation, or by such other means as we and the Agent may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the sale of the common stock on our behalf, the Agent will deemed to be an &#x201c;underwriter&#x201d; within the meaning of the Securities Act and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the Agent against certain civil liabilities, including liabilities under the Securities Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The offering of our common stock pursuant to this prospectus will terminate upon the earlier of (i)&#x00a0;the issuance and sale of all shares of our common stock subject to this prospectus, or (ii)&#x00a0;the termination of the sales agreement as permitted therein.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Agent and its respective affiliates may in the future provide various investment banking and other financial services for us and our affiliates for which services it may in the future receive customary fees.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. We are filing a copy of the sales agreement on a Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT> filed on or about the date of this prospectus supplement.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-10</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99510"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LEGAL MATTERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The validity of the common stock offered hereby will be passed upon for us by Honigman LLP, Kalamazoo, Michigan. Duane Morris LLP, New&#x00a0;York, New&#x00a0;York, is acting as counsel to the Agent in connection with this offering.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99511"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EXPERTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements as of September&#x00a0;30, 2022 and 2021 and for each of the two&#x00a0;years in the period ended September&#x00a0;30, 2022 incorporated by reference in this prospectus supplement have been so incorporated in reliance on the report of Baker Tilly US, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding the Company&#x2019;s ability to continue as a going concern.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99512"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form&#x00a0;S<FONT CLASS="nobreak">-3</FONT> we filed with the SEC under the Securities Act and do not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus supplement or the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange&#x00a0;Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC.&#x00a0;You may read and copy information filed by us with the SEC at the SEC&#x2019;s public reference section, 100 F Street, N.E., Washington, D.C. 20549. Information regarding the operation of the public reference section can be obtained by calling&#x00a0;1<FONT CLASS="nobreak">-800-SEC-0330</FONT>. The SEC also maintains an Internet site at http://www.sec.gov that contains reports, statements and other information about issuers, such as us, who file electronically with the SEC.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-11</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99513"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INCORPORATION BY REFERENCE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The SEC allows us to &#x201c;incorporate by reference&#x201d; into this prospectus supplement the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement, and any information contained in documents that we may file later with the SEC will automatically update and supersede the information contained in documents filed earlier with the SEC or contained in this prospectus supplement. We incorporate by reference in this prospectus supplement the documents listed below and any future filings that we may make with the SEC under Sections 13(a), 13(c),<FONT CLASS="nobreak"> </FONT>14, or 15(d)&#x00a0;of the Exchange&#x00a0;Act prior to the termination of the offering under this prospectus supplement; provided, however, that we are not incorporating, in each case, any documents or information deemed to have been furnished and not filed in accordance with SEC rules:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1500198/000121390022081897/f10k2022_neuroone.htm">Form 10-K</A> for the year ended September<FONT CLASS="nobreak">&#x00a0;</FONT>30, 2022, filed with the SEC on December<FONT CLASS="nobreak">&#x00a0;</FONT>21, 2022;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our Current Reports on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390022065984/ea167480-8k_neuroone.htm">Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT></A>, filed with the SEC on October<FONT CLASS="nobreak">&#x00a0;</FONT>25, 2022; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the description of our common stock contained in the &#x201c;Description of Securities&#x201d; filed as Exhibit 4.0 to our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1500198/000121390022081897/f10k2022_neuroone.htm">Form 10-K</A> for the year ended September<FONT CLASS="nobreak">&#x00a0;</FONT>30, 2022, and any amendment or report filed with the SEC for the purpose of updating the description.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, all documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)&#x00a0;of the Exchange&#x00a0;Act subsequent to the date of filing the registration statement that includes this prospectus and prior to the filing of a post<FONT CLASS="nobreak">-effective</FONT> amendment to the registration statement containing this prospectus, which indicates that all securities offered have been sold or which deregisters all of such securities then remaining unsold, shall be deemed to be incorporated by reference in this prospectus and to be a part hereof from the respective dates of filing of such documents. However, we are not incorporating by reference, in each case, any information or documents that are deemed to be furnished and not filed in accordance with SEC rules, including any information furnished pursuant to Items 2.02 or 7.01 of Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT> or related exhibits furnished pursuant to Item&#x00a0;9.01 of Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:</P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">NeuroOne Medical Technologies Corporation<BR>7599 Anagram Drive<BR>Eden Prairie, Minnesota 55344</P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">(952)&#x00a0;426<FONT CLASS="nobreak">-1383</FONT><BR>Attention: Secretary</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will not, however, send exhibits to these documents unless the exhibits are specifically incorporated by reference in those documents or deemed to be incorporated by reference in this prospectus. In addition, you may obtain a copy of these filings from the SEC as described above in the section entitled &#x201c;Where You Can Find More Information.&#x201d;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">S-12</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PROSPECTUS</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="tneuro_logo.jpg" STYLE="width:399.36px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">$150,000,000</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">Common Stock<BR>Preferred Stock<BR>Debt Securities<BR>Warrants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, we may offer and sell an aggregate amount of up to $150,000,000 of any combination of the securities described in this prospectus, either individually or in combination, in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus describes some of the general terms that may apply to an offering of our securities that we may offer. Each time we offer securities, we will provide specific terms of the securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-indent:24pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol &#x201c;NMTC.&#x201d; On June&#x00a0;3, 2021, the last reported sale price of our common stock was $7.49 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on Nasdaq or any securities market or other exchange of the securities, if any, covered by the applicable prospectus supplement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#x201c;Plan of Distribution&#x201d; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over<FONT CLASS="nobreak">-allotment</FONT> options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-indent:24pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#x201c;Risk Factors&#x201d; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page&#x00a0;6 of this prospectus.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-indent:24pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</FONT></P>
		<P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:40pt;margin-top:40pt;">The date of this prospectus is June<FONT CLASS="nobreak"> </FONT>14, 2021.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>


	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">

					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99601">ABOUT THIS PROSPECTUS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ii</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99602">SUMMARY</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99603">RISK FACTORS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">6</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99604">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">7</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99605">USE OF PROCEEDS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">8</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99606">DESCRIPTION OF COMMON STOCK</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">9</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99607">DESCRIPTION OF PREFERRED STOCK</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99608">DESCRIPTION OF DEBT SECURITIES</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">13</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99609">DESCRIPTION OF WARRANTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">19</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99610">LEGAL OWNERSHIP OF SECURITIES</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">21</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99611">PLAN OF DISTRIBUTION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">24</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99612">LEGAL MATTERS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99613">EXPERTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99614">WHERE YOU CAN FIND MORE INFORMATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">26</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99615">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">27</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99601"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">ABOUT THIS PROSPECTUS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus is a part of a registration statement on Form&#x00a0;S<FONT CLASS="nobreak">-3</FONT> that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &#x201c;shelf&#x201d; registration process. Under this shelf registration statement, we may offer and sell, either individually or in any combination, the securities described in this prospectus in one or more offerings from time to time up to a total aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities we may offer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#x201c;Incorporation of Certain Information by Reference,&#x201d; before investing in any of the securities offered.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-indent:24pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we may authorize for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, the accompanying prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or the time of any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus contains and/or incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and/or the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#x201c;Risk Factors&#x201d; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus and the information incorporated herein by reference contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#x201c;Where You Can Find More Information.&#x201d;</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;margin-top:8pt;">This prospectus contains references to trademarks belonging to us and other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">&#x00ae;</FONT> or &#x2122; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#x2019; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ii</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>





	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99602"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SUMMARY</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The following summary highlights information contained elsewhere in this prospectus or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#x201c;Risk Factors&#x201d; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used in this prospectus, unless otherwise indicated, the terms&#x00a0;<FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; &#x201c;the Company&#x201d;</FONT> and <FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">&#x201c;NeuroOne&#x201d; </FONT>refer to NeuroOne Medical Technologies Corporation, a Delaware corporation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business Overview</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are developing our cortical sheet and depth electrode technology to provide solutions for diagnosis through cEEG recording and sEEG recording and treatment through spinal cord stimulation, brain stimulation and ablation, all in one product. A cEEG is a continuous recording of the electrical activity of the brain that identifies the location of irregular brain activity, which information is required for proper treatment. cEEG recording involves an invasive surgical procedure, referred to as a craniotomy. sEEG involves a less invasive procedure whereby doctors place electrodes in targeted brain areas by drilling small holes through the skull. Both methods of seizure diagnosis are used to identify areas of the brain where epileptic seizures originate in order to precisely locate the seizure source for therapeutic treatment if possible.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deep brain stimulation, or DBS, therapies involve activating or inhibiting the brain with electricity that can be given directly by electrodes on the surface or implanted deeper in the brain via depth electrodes. Introduced in 1987, this procedure involves implanting a power source referred to as a neurostimulator, which sends electrical impulses through implanted depth electrodes, to specific targets in the brain for the treatment of disorders such as Parkinson&#x2019;s disease, essential tremor, dystonia, and chronic pain. Alzheimer&#x2019;s is another indication evaluating the effects of DBS.&#x00a0;Unlike ablative technologies, the effects of DBS are reversible.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">RF ablation is a procedure that uses radiofrequency under the electrode contacts that is directed to the site of the brain tissue that is targeted for removal. The process involves delivering energy to the contacts, thereby heating them and destroying the brain tissue. The ablation does not remove the tissue. Rather, it is left in place and typically scar tissue forms in the place where the ablation occurs. This procedure is also known as brain lesioning as it causes irreversible lesions.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failed back surgery syndrome (&#x201c;FBSS&#x201d;) is a condition that produces chronic lower back/leg pain due to one or more failed back surgeries. Typically, it is related to patients that suffer with pain after surgery of the lumbar spine for degenerative disc disease. Re<FONT CLASS="nobreak">-operations</FONT> are usually not recommended for these patients due to low success rates. These patients experience greater levels of pain, a lower quality of life, varying levels of disability and higher rate of unemployment. Spinal cord stimulation works by placing an electrodes(s)&#x00a0;in a targeted area of the spine and then connected to an implantable pulse generator that sends electrical stimulation to the electrode to block the pain signals from reaching the brain.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our cortical sheet electrode and depth electrode technology has been tested over the&#x00a0;years by both WARF, the owners of our licensed patents, and Mayo Clinic located in Rochester, Minnesota, in both pre<FONT CLASS="nobreak">-clinical</FONT> models as well as through an IRB approval at Mayo Clinic for clinical research. Regarding our ablation electrode, the Cleveland Clinic has performed testing in bench top models and pre<FONT CLASS="nobreak">-clinical</FONT> (or animal testing) modes. These pre<FONT CLASS="nobreak">-clinical</FONT> tests have demonstrated that the technology is capable of recording, ablation and acute stimulation, although our technology remains in product development (meaning that additional trials will be needed prior to it being approved for sale by the U.S.&#x00a0;Food and Drug Administration (the &#x201c;FDA&#x201d;)) for all of the recording (or diagnostic) and therapeutic modalities.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Strategy</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our goal is to be the global leader in cEEG and sEEG recording, deep brain stimulation and ablation, owning the procedure from diagnosis through treatment. The key elements of our strategy include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Introduce cortical strip and grid electrodes for the diagnosis of epilepsy in United&#x00a0;States:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>In December&#x00a0;2019, we announced that we received U.S.&#x00a0;FDA 510(k)&#x00a0;clearance to market our thin film cortical electrode technology for temporary (less than 30&#x00a0;days) recording, monitoring, and stimulation on the surface of the brain. Our initial product offering will be placed through traditional surgical means involving a craniotomy until such time, if any, that we launch our minimally invasive procedure. We believe, due to physician feedback, that our technology under development would represent a major improvement over existing cortical electrodes for the recording of brain activity. We are initially targeting epilepsy as we believe this is a clinical area of great need and a market that is underserved with a quick path to commercialization. We believe the largest and quickest<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-market</FONT> geography for our cortical strip and grid technology under development is in the United&#x00a0;States for a number of reasons, including the following: (i)&#x00a0;many industry sources believe there is a large underserved U.S.&#x00a0;market, (ii)&#x00a0;healthy procedural reimbursement for centers and physicians, (iii)&#x00a0;robust average selling prices, (iv)&#x00a0;physician enthusiasm for our technology under development.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Launch depth electrodes for sEEG recording:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Given the reluctance of patients to undergo epilepsy surgery due to its invasiveness, a number of epilepsy centers have adopted the use of depth electrodes, which are placed by drilling small holes into the patient&#x2019;s cranium, thereby avoiding a craniotomy. We believe our technology will offer advantages to current depth electrode technology and will enable us to offer a therapeutic solution using this technology in the future. As we develop our technology, we plan to release further information about the expected advantages of our technology over currently available therapies.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Introduce minimally invasive delivery system for cortical electrodes:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Cortical electrodes generally require a craniotomy, which is a very invasive procedure that can cause patient complications. Because of this, many patients have opted to not have epilepsy surgery, instead accepting the consequences and risks associated with epilepsy. We intend to develop a procedure that may include a delivery system placed through a small circular incision in the skull for implantation of the cortical grid and strip electrodes. We believe this will increase patient willingness to accept the surgery and increase market penetration. Until we are able to develop this procedure, if at all, our initial product offering will be placed through traditional surgical means involving a craniotomy and may be less likely to be adopted by physicians and patients due to unwillingness of patients to undergo epilepsy surgery.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Develop percutaneous placed electrodes for spinal cord stimulation with scalable contact configurations:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Given that many surgically placed technologies have become less invasive due to patient and physician demands, we believe that our flexible thin film technology will allow for percutaneous placement, thus potentially eliminating the need to make a surgical incision. By leveraging our existing FDA cleared cortical electrode technology, we may be able to offer the ability to improve precision of where the stimulation is delivered. NeuroOne&#x2019;s platform thin film technology has the capability to increase the number of contacts in a similar footprint that has fewer contacts.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;font-style:normal;font-weight:bold;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Utilize these core technologies to develop all in one diagnostic and therapeutic solutions:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Patients currently undergo one surgical procedure for diagnosis (either to have a cortical electrode placed via a craniotomy or depth electrodes placed via holes drilled into the skull) and, hopefully after the brain recordings successfully indicate where the affected brain tissue is located, a second procedure or surgery is then required to treat the patient. There is strong physician interest in being able to perform both the diagnostic and therapeutic procedure concurrently. We are developing our technology with the goal of being able to offer this benefit although there can be no assurance that we will be able to do so. We are pursuing cortical grid, strip and depth electrode technology that can record brain activity (diagnose), ablate brain tissue and also provide both acute and long term stimulation. The technology has demonstrated these functions in acute and short term animal models; however, additional development is required to offer a device that has long term therapeutic application. These therapeutic technologies are </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">expected to require more robust regulatory approvals for the United&#x00a0;States, ranging from a 510(k)&#x00a0;with human clinical data to PMAs. We will engage the FDA at the proper time to determine the most efficient clinical path.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Gain approval for other brain or motor related disorders such as Parkinson&#x2019;s with the therapeutic technologies developed for epilepsy:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>While we are developing our technology for the diagnosis and treatment of epilepsy, we believe that our technology has strong application and utilization for other brain or motor related disorders such as Parkinson&#x2019;s disease, dystonia, essential tremors and facial pain as these diseases are currently treated with DBS if medications are not effective. As previously mentioned, we are planning to offer electrodes that can be implanted for long term stimulation applications, but such use will require that we pursue additional approvals from the FDA and any international regulatory bodies where we seek to commercialize our technology.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Explore partnerships with other companies that leverage our core technology:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Given that our technology enables, complements and/or competes with a number of companies that are in the market or attempting to enter the market with diagnostic or therapeutic technologies to treat brain related disorders, we believe there may be opportunities to establish mutually beneficial relationships. In addition, our technology may have application in cardiovascular, orthopedic and pain related indications that could benefit from a hi<FONT CLASS="nobreak">-fidelity</FONT> thin film electrode product that can provide stimulation and/or ablation therapies.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Investigate the potential applications associated with Artificial Intelligence:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>We have been informed by some of our corporate advisors that the ability to offer scale<FONT CLASS="nobreak">-able</FONT> electrode technology that can provide thousands of electrodes in the brain may be helpful in treating medical conditions that may benefit from using artificial intelligence. The Company has formed an advisory board that will provide guidance to the Company as we continue to explore the opportunities in this exciting field.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Corporate Information</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">NeuroOne Medical Technologies Corporation was originally incorporated under the laws of the State of Nevada under the name Original Source Entertainment, Inc. On July&#x00a0;20, 2017, we consummated a reverse acquisition transaction to acquire a privately<FONT CLASS="nobreak">-held</FONT> company, NeuroOne, Inc., and as a result, NeuroOne, Inc. became our wholly<FONT CLASS="nobreak">-owned</FONT> subsidiary. We refer to this transaction as the &#x201c;Acquisition.&#x201d; On December&#x00a0;30, 2019, NeuroOne, Inc. merged with and into NeuroOne Medical Technologies Corporation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The Securities We May Offer</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, up to a total aggregate offering price of $150,000,000 from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>designation or classification;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>aggregate principal amount or aggregate offering price;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>maturity, if applicable;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>original issue discount, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>rates and times of payment of interest or dividends, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>redemption, conversion, exchange or sinking fund terms, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>ranking, if applicable;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictive covenants, if any;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>voting or other rights, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>important U.S.&#x00a0;federal income tax considerations.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the names of those underwriters or agents;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>applicable fees, discounts and commissions to be paid to them;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>details regarding over<FONT CLASS="nobreak">-allotment</FONT> options, if any; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the estimated net proceeds to us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Common Stock.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Holders of our common stock are entitled to one vote per share for the election of directors and on all other matters that require stockholder approval, as further set forth herein under the heading &#x201c;Description of Common Stock.&#x201d; Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock. Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus) related to any common stock being offered.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Preferred Stock.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our board of directors will determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in a certificate of designation relating to that series. We will file as an exhibit to, or incorporate by reference into, the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplement (and any related free writing prospectus) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Debt Securities.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>From time to time, we may issue debt securities in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory or at the holder&#x2019;s option and would be at prescribed conversion rates.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any debt securities issued under this prospectus will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under the heading &#x201c;Description of Debt Securities.&#x201d; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indenture(s)&#x00a0;and any supplemental indentures that contain the terms of the debt securities. We have filed a form of indenture as an exhibit to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, supplemental indentures and forms of debt securities containing the terms of the debt securities being offered.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Warrants.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>From time to time, we may issue warrants for the purchase of common stock, preferred stock and/or debt securities, in one or more series, from time to time. We may issue warrants independently or in combination with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants under the heading &#x201c;Description of Warrants.&#x201d; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that we may offer as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, the form of warrant or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants may be issued under a warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99603"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISK FACTORS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described under &#x201c;Risk Factors&#x201d; in the applicable prospectus supplement, together with all of the other information under similar headings appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the incorporated documents also contain forward<FONT CLASS="nobreak">-looking</FONT> statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward<FONT CLASS="nobreak">-looking</FONT> statements as a result of certain factors, including the risks mentioned elsewhere in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading &#x201c;Risk Factors&#x201d; included in our most recent Annual Report on Form&#x00a0;10<FONT CLASS="nobreak">-K</FONT>, which is on file with the SEC and incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99604"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SPECIAL NOTE REGARDING </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">FORWARD-LOOKING</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> STATEMENTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus, including the documents that we incorporate by reference, contains forward<FONT CLASS="nobreak">-looking</FONT> statements within the meaning of Section&#x00a0;27A of the Securities Act&#x00a0;of&#x00a0;1933, as amended (the&#x00a0;&#x201c;Securities Act&#x201d;), and Section&#x00a0;21E of the Exchange&#x00a0;Act&#x00a0;of&#x00a0;1934, as amended (the&#x00a0;&#x201c;Exchange&#x00a0;Act&#x201d;). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward<FONT CLASS="nobreak">-looking</FONT>. These statements are often, but are not always, made through the use of words or phrases such as &#x201c;anticipates,&#x201d; &#x201c;could,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; &#x201c;may,&#x201d; &#x201c;potential,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;estimates,&#x201d; &#x201c;plans,&#x201d; &#x201c;projects,&#x201d; &#x201c;predicts,&#x201d; &#x201c;targets,&#x201d; &#x201c;continuing,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;expects,&#x201d; &#x201c;management believes,&#x201d; &#x201c;we believe,&#x201d; &#x201c;we intend&#x201d; and similar words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward<FONT CLASS="nobreak">-looking</FONT> statements are qualified in their entirety by reference to the factors discussed throughout this prospectus, and in particular those factors included in the sections entitled &#x201c;Risk Factors&#x201d; in this prospectus and our most recent Annual Report on Form&#x00a0;10<FONT CLASS="nobreak">-K</FONT>, which is on file with the SEC and incorporated herein by reference.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the factors referred to in the preceding paragraph could cause actual results or outcomes to differ materially from those expressed in any forward<FONT CLASS="nobreak">-looking</FONT> statements we make, you should not place undue reliance on any such forward<FONT CLASS="nobreak">-looking</FONT> statements. Further, any forward<FONT CLASS="nobreak">-looking</FONT> statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward<FONT CLASS="nobreak">-looking</FONT> statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward<FONT CLASS="nobreak">-looking</FONT> statements.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You should carefully read this prospectus, any applicable prospectus supplement&#x00a0;and any related free writing prospectus, together with the information incorporated herein or therein by reference as described under the section titled &#x201c;Incorporation of Certain Information by Reference,&#x201d; and with the understanding that our actual future results may materially differ from what we expect.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as required by law, forward<FONT CLASS="nobreak">-looking</FONT> statements speak only as of the date they are made, and we assume no obligation to update any forward<FONT CLASS="nobreak">-looking</FONT> statements publicly, or to update the reasons why actual results could differ materially from those anticipated in any forward<FONT CLASS="nobreak">-looking</FONT> statements, even if new information becomes available.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99605"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">USE OF PROCEEDS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will retain broad discretion over the use of the net proceeds from our sale of securities offered hereby. Except as described in any applicable prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you in connection with a specific offering, we currently anticipate using the net proceeds from our sale of securities offered hereby, if any, primarily for general corporate purposes. We may also use a portion of such net proceeds to in<FONT CLASS="nobreak">-license</FONT>, acquire or invest in businesses or products that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99606"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DESCRIPTION OF COMMON STOCK</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following summary description of our common stock is based on the provisions of our third amended and restated certificate of incorporation, as amended, as well as our second amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law, as amended (the &#x201c;DGCL&#x201d;). This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, as amended, our bylaws and the Delaware General Corporation Law. For information on how to obtain copies of our certificate of incorporation, as amended, and our bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#x201c;Where You Can Find More Information.&#x201d; We refer in this section to certificate of incorporation, as amended, and our bylaws as our &#x201c;certificate of incorporation&#x201d; and our &#x201c;bylaws&#x201d;, respectively.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our authorized capital stock consists of 100,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock, par value $0.001 per share, and 10,000,000<FONT CLASS="nobreak"> </FONT>shares of preferred stock, par value $0.001 per share.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders of the Company&#x2019;s common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights. Therefore, holders of a majority of the shares of common stock voting for the election of directors can elect all of the directors. Holders of the Company&#x2019;s common stock representing a majority of the voting power of the Company&#x2019;s capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of a majority of the Company&#x2019;s outstanding common stock is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to the Company&#x2019;s certificate of incorporation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders of the Company&#x2019;s common stock are entitled to share in all dividends that the Company&#x2019;s board of directors, in its discretion, declares from legally available funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The Company&#x2019;s common stock has no pre<FONT CLASS="nobreak">-emptive</FONT> rights, no conversion rights and there are no redemption provisions applicable to the Company&#x2019;s common stock.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#x2019;s certificate of incorporation authorize the issuance of 10,000,000<FONT CLASS="nobreak"> </FONT>shares of &#x201c;blank check&#x201d; preferred stock, par value $0.001 per share, in one or more series, subject to any limitations prescribed by law, without further vote or action by the stockholders. Each such series of preferred stock shall have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Registration Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#x00a0;12, 2021, we entered into a Common Stock and Warrant Purchase Agreement (the &#x201c;2021 Purchase Agreement&#x201d;) with certain accredited investors, pursuant to which the Company, in a private placement, agreed to issue and sell an aggregate of 12,500,000<FONT CLASS="nobreak"> </FONT>shares of common stock and warrants to purchase an aggregate of 12,500,000<FONT CLASS="nobreak"> </FONT>shares of common stock, at an aggregate purchase price of $1.00 per share of common stock and corresponding warrant, resulting in total gross proceeds of $12.5&#x00a0;million before deducting placement agent fees and estimated offering expenses. The private placement closed on January&#x00a0;14, 2021.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the private placement, we agreed to file, within 30&#x00a0;days of the closing of the private placement, a registration statement on Form&#x00a0;S<FONT CLASS="nobreak">-1</FONT> with the SEC covering the resale of the shares of common stock and warrants sold in the private placement and the shares of common stock underlying the warrants. Such registration statement was filed with the SEC on February&#x00a0;10, 2021 and declared effective by the SEC on March&#x00a0;8, 2021. We have agreed to use our best efforts to keep the registration statement continuously effective until the earlier of (i)&#x00a0;the date that all registrable securities have been sold, pursuant to such registration statement or pursuant to Rule&#x00a0;144, or (ii)&#x00a0;the date that all registrable may be sold without volume or manner<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-sale</FONT> restrictions pursuant to Rule&#x00a0;144 and without the requirement that we are in compliance with the current public information requirement under Rule&#x00a0;144.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Anti-Takeover</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Effects</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are subject to Section&#x00a0;203 of the Delaware General Corporation Law, or Section&#x00a0;203. Section&#x00a0;203 generally prohibits a public Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a period of three&#x00a0;years after the date of the transaction in which the person became an interested stockholder, unless:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (a)&#x00a0;shares owned by persons who are directors and also officers and (b)&#x00a0;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on or subsequent to the consummation of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66&#x2154;% of the outstanding voting stock which is not owned by the interested stockholder.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#x00a0;203 defines a business combination to include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any merger or consolidation involving the corporation and the interested stockholder; any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, Section&#x00a0;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Securities Exchange Listing</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;NMTC.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The transfer agent and registrar for our common stock is&#x00a0;Action Stock Transfer Corporation.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99607"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DESCRIPTION OF PREFERRED STOCK</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have authority to issue up to 10,000,000<FONT CLASS="nobreak"> </FONT>shares of preferred stock, par value $0.001 per share. All of our authorized preferred stock is undesignated.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may issue any class of preferred stock in any series. Our board of directors has the authority to establish and designate series, and to fix the number of shares included in each such series and to determine or alter for each such series, such voting powers, designation, preferences, and relative participating, optional, or other rights and such qualifications, limitations or restrictions thereof. Our board of directors is not restricted in repurchasing or redeeming such stock while there is any arrearage in the payment of dividends or sinking fund installments. Our board of directors is authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. The number of authorized shares of preferred stock may be increased or decreased, but not below the number of shares thereof then outstanding, by the affirmative vote of the holders of a majority of the common stock, without a vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of preferred stock.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to issuance of shares of any series of preferred stock, our board of directors is required by Delaware law to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware. The certificate of designation fixes for each class or series the terms, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications and terms or conditions of redemption for each class or series. Any shares of preferred stock will, when issued, be fully paid and non<FONT CLASS="nobreak">-assessable</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For any series of preferred stock that we may issue, our board of directors will determine and the prospectus supplement relating to such series will describe:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the purchase price, title and stated value of the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the number of shares of the preferred stock offered, the liquidation preference per share and the offering price of the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the dividend rate(s), period(s)&#x00a0;or payment date(s)&#x00a0;or method(s)&#x00a0;of calculation applicable to the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether dividends are cumulative or non<FONT CLASS="nobreak">-cumulative</FONT> and, if cumulative, the date from which dividends on the preferred stock will accumulate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our right, if any, to defer payment of dividends and the maximum length of any such deferral period;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the procedures for auction and remarketing, if any, for the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the provisions for a sinking fund, if any, for the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the provision for redemption, if applicable, of the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any listing of the preferred stock on any securities exchange;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock, including the conversion price or manner of calculation and conversion period;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>voting rights, if any, of the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether interests in the preferred stock will be represented by depositary shares;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a discussion of any material or special U.S.&#x00a0;federal income tax considerations applicable to the preferred stock;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the class or series of preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Delaware law provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation then in effect provides otherwise, the number of authorized shares of such class or change the powers, preferences or special rights of such class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99608"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DESCRIPTION OF DEBT SECURITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act&#x00a0;of&#x00a0;1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from, reports that we file with the SEC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">General</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may issue the debt securities issued under the indenture as &#x201c;discount securities,&#x201d; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#x201c;original issue discount,&#x201d; or OID, for U.S.&#x00a0;federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S.&#x00a0;federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the title of the series of debt securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any limit upon the aggregate principal amount that may be issued;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the maturity date or dates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the form of the debt securities of the series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the applicability of any guarantees;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our right, if any, to defer payment of interest and the maximum length of any such deferral period;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#x2019;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#x2019; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additions to or changes in the provisions relating to satisfaction and discharge of the indenture;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the currency of payment of debt securities if other than U.S.&#x00a0;dollars and the manner of determining the equivalent amount in U.S.&#x00a0;dollars;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether interest will be payable in cash or additional debt securities at our or the holders&#x2019; option and the terms and conditions upon which the election may be made;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#x201c;United&#x00a0;States person&#x201d; for federal tax purposes;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any restrictions on transfer, sale or assignment of the debt securities of the series; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Conversion or Exchange Rights</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consolidation, Merger or Sale</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than any subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Events of Default under the Indenture</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90&#x00a0;days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&#x00a0;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if specified events of bankruptcy, insolvency or reorganization occur.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the direction so given by the holder is not in conflict with any law or the applicable indenture; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the holder has given written notice to the trustee of a continuing event of default with respect to that series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90&#x00a0;days after the notice, request and offer.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Modification of Indenture; Waiver</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to comply with the provisions described above under &#x201c;Description of Debt Securities&#x00a0;&#x2014;&#x00a0;Consolidation, Merger or Sale;&#x201d;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to provide for uncertificated debt securities in addition to or in place of certificated debt securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#x201c;Description of Debt Securities&#x00a0;&#x2014;&#x00a0;General&#x201d; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>extending the fixed maturity of any debt securities of any series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Discharge</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>provide for payment;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>register the transfer or exchange of debt securities of the series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>replace stolen, lost or mutilated debt securities of the series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>pay principal of and premium and interest on any debt securities of the series;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>maintain paying agencies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>hold monies for payment in trust;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>recover excess money held by the trustee;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>compensate and indemnify the trustee; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>appoint any successor trustee.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Form, Exchange and Transfer</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book<FONT CLASS="nobreak">-entry</FONT> securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book<FONT CLASS="nobreak">-entry</FONT>, a description of terms relating to any book<FONT CLASS="nobreak">-entry</FONT> securities will be set forth in the applicable prospectus supplement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If we elect to redeem the debt securities of any series, we will not be required to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15&#x00a0;days before the&#x00a0;day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the&#x00a0;day of the mailing; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Information Concerning the Trustee</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Payment and Paying Agents</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two&#x00a0;years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Governing Law</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New&#x00a0;York, except to the extent that the Trust Indenture Act&#x00a0;of&#x00a0;1939 is applicable.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99609"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DESCRIPTION OF WARRANTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have filed forms of the warrant agreements as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">General</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the applicable prospectus supplement, we will describe the terms of the series of warrants being offered, including, to the extent applicable:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the title of such securities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the offering price or prices and aggregate number of warrants offered;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the currency or currencies for which the warrants may be purchased;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the date on and after which the warrants and the related securities will be separately transferable;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the minimum or maximum amount of such warrants which may be exercised at any one time</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the terms of any rights to redeem or call the warrants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the terms of any rights to force the exercise of the warrants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the dates on which the right to exercise the warrants will commence and expire;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the manner in which the warrant agreements and warrants may be modified;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a discussion of any material or special U.S.&#x00a0;federal income tax considerations of holding or exercising the warrants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the terms of the securities issuable upon exercise of the warrants; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Exercise of Warrants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable on such exercise. If less than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Governing Law</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New&#x00a0;York.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Enforceability of Rights by Holders of Warrants</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99610"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LEGAL OWNERSHIP OF SECURITIES</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#x201c;holders&#x201d; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#x201c;indirect holders&#x201d; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book<FONT CLASS="nobreak">-entry</FONT> form or in street name will be indirect holders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Book-Entry</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Holders</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may issue securities in book<FONT CLASS="nobreak">-entry</FONT> form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#x2019;s book<FONT CLASS="nobreak">-entry</FONT> system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#x2019;s book<FONT CLASS="nobreak">-entry</FONT> system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Street Name Holders</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#x201c;street name.&#x201d; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Legal Holders</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holder, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Special Considerations for Indirect Holders</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold securities through a bank, broker or other financial institution, either in book<FONT CLASS="nobreak">-entry</FONT> form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>how it handles securities payments and notices;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether it imposes fees or charges;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>how it would handle a request for the holders&#x2019; consent, if ever required;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if the securities are in book<FONT CLASS="nobreak">-entry</FONT> form, how the depositary&#x2019;s rules and procedures will affect these matters.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Global Securities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each security issued in book<FONT CLASS="nobreak">-entry</FONT> form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC, New&#x00a0;York, New&#x00a0;York, will be the depositary for all securities issued in book<FONT CLASS="nobreak">-entry</FONT> form.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#x201c;&#x2014;&#x00a0;Special Situations When a Global Security Will Be Terminated.&#x201d; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book<FONT CLASS="nobreak">-entry</FONT> clearing system or decide that the securities may no longer be held through any book<FONT CLASS="nobreak">-entry</FONT> clearing system.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Special Considerations for Global Securities</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As an indirect holder, an investor&#x2019;s rights relating to a global security will be governed by the account rules of the investor&#x2019;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If securities are issued only as global securities, an investor should be aware of the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an investor cannot cause the securities to be registered in his or her name, and cannot obtain non<FONT CLASS="nobreak">-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non<FONT CLASS="nobreak">-book</FONT><FONT CLASS="nobreak">-entry</FONT> form;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the depositary&#x2019;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#x2019;s interest in the global security;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we and any applicable trustee have no responsibility for any aspect of the depositary&#x2019;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book<FONT CLASS="nobreak">-entry</FONT> system use immediately available funds, and your broker or bank may require you to do so as well; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>financial institutions that participate in the depositary&#x2019;s book<FONT CLASS="nobreak">-entry</FONT> system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Special Situations When a Global Security Will Be Terminated</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90&#x00a0;days;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if we notify any applicable trustee that we wish to terminate that global security; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99611"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PLAN OF DISTRIBUTION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>at a fixed price or prices, which may be changed;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>at market prices prevailing at the time of sale;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>at prices related to such prevailing market prices; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>at negotiated prices.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may also sell equity securities covered by this registration statement in an &#x201c;at the market offering&#x201d; as defined in Rule&#x00a0;415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on or through the facilities of Nasdaq or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to or through a market maker other than on Nasdaq or such other securities exchanges or quotation or trading services.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the name or names of any underwriters, dealers or agents, if any;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the purchase price of the securities and the proceeds we will receive from the sale;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any over<FONT CLASS="nobreak">-allotment</FONT> options under which underwriters may purchase additional securities from us;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any agency fees or underwriting discounts and other items constituting agents&#x2019; or underwriters&#x2019; compensation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any public offering price;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any discounts or concessions allowed or reallowed or paid to dealers; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any securities exchange or market on which the securities may be listed.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best<FONT CLASS="nobreak">-efforts</FONT> basis for the period of its appointment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over<FONT CLASS="nobreak">-the</FONT><FONT CLASS="nobreak">-counter</FONT> market or otherwise.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on Nasdaq in accordance with Rule&#x00a0;103 of Regulation&#x00a0;M, during the business&#x00a0;day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#x2019;s bid, however, the passive market maker&#x2019;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99612"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">LEGAL MATTERS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon for us by Honigman LLP, Kalamazoo, Michigan. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99613"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EXPERTS</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements as of September&#x00a0;30, 2020 and 2019 and for each of the two&#x00a0;years in the period ended September&#x00a0;30, 2020 incorporated by reference in this Prospectus have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding the Company&#x2019;s ability to continue as a going concern.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99614"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This prospectus is part of the registration statement on Form&#x00a0;S<FONT CLASS="nobreak">-3</FONT> we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. We file reports, proxy statements and other information with the SEC in accordance with the Exchange&#x00a0;Act. You may read and copy our reports, proxy statements and other information filed with the SEC on the SEC&#x2019;s website at&#x00a0;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">http:</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">//</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.sec.gov.</FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-2" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99615"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We &#x201c;incorporate by reference&#x201d; certain documents and information that we have filed with the SEC into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is deemed to be part of this prospectus, except for any information superseded by information contained directly in this prospectus. This prospectus incorporates by reference:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our Annual Report on&#x00a0;Form&#x00a0;10<FONT CLASS="nobreak">-K</FONT>&#x00a0;for the fiscal year ended <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390020041661/f10k2020_neuroonemedical.htm">September<FONT CLASS="nobreak">&#x00a0;</FONT>30, 2020</A>, filed with the SEC on&#x00a0;December<FONT CLASS="nobreak">&#x00a0;</FONT>9, 2020&#x00a0;as amended on&#x00a0;<A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021004908/f10k2020a1_neuroonemedical.htm">January<FONT CLASS="nobreak">&#x00a0;</FONT>28, 2021</A>&#x00a0;and&#x00a0;<A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021008993/f10k2020a2_neuroonemedical.htm">February<FONT CLASS="nobreak">&#x00a0;</FONT>12, 2021</A>;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our Quarterly Reports on&#x00a0;Form&#x00a0;10<FONT CLASS="nobreak">-Q</FONT>&#x00a0;for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021009675/f10q1220_neuroone.htm">December<FONT CLASS="nobreak">&#x00a0;</FONT>31, 2020</A>, filed with the SEC on February<FONT CLASS="nobreak">&#x00a0;</FONT>16, 2021, and the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021026426/f10q0321_neuroonemedical.htm">March<FONT CLASS="nobreak">&#x00a0;</FONT>31, 2021</A>, filed with the SEC on May<FONT CLASS="nobreak">&#x00a0;</FONT>14, 2021;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our Current Reports on&#x00a0;Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT>&#x00a0;filed with the SEC on&#x00a0;<A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390020030207/ea127849-8k_neuroonemedi.htm">October<FONT CLASS="nobreak">&#x00a0;</FONT>6, 2020</A>,&#x00a0;<A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021000810/ea132820-8k_neuroone.htm">January<FONT CLASS="nobreak">&#x00a0;</FONT>7, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021002402/ea133294-8k_neuroone.htm">January<FONT CLASS="nobreak"> </FONT>15, 2021</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1500198/000121390021010996/ea136246-8k_neuromedtech.htm">February<FONT CLASS="nobreak">&#x00a0;</FONT>23, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021018989/ea138690-8k_neuroone.htm">March<FONT CLASS="nobreak">&#x00a0;</FONT>31, 2021</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1500198/000121390021029116/ea141619-8k_neuroonemed.htm">May<FONT CLASS="nobreak">&#x00a0;</FONT>25, 2021</A>; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the description of our Common Stock in Exhibit 4.2 to our Annual Report on&#x00a0;<A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390020041661/f10k2020_neuroonemedical.htm">Form&#x00a0;10<FONT CLASS="nobreak">-K</FONT></A>&#x00a0;for the fiscal year ended September<FONT CLASS="nobreak">&#x00a0;</FONT>30, 2020, filed on December<FONT CLASS="nobreak">&#x00a0;</FONT>9, 2020.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)&#x00a0;of the Exchange&#x00a0;Act, except as to any portion of any report or document that is not deemed filed under such provisions, (i)&#x00a0;on or after the date of filing of the registration statement containing this prospectus and prior to the effectiveness of the registration statement and (ii)&#x00a0;on or after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the date of filing of those documents. Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item&#x00a0;2.02 or 7.01 of Form&#x00a0;8<FONT CLASS="nobreak">-K</FONT>.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These documents may also be accessed on our website at&#x00a0;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.n1mtc.com</FONT>. Information contained in, or accessible through, our website is not a part of this prospectus. The SEC also maintains a website at <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.sec.gov </FONT>that contains reports, proxy and information statements, and information regarding issuers that file electronically with the SEC.</P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We will provide without charge to each person, including any beneficial owners, to whom this prospectus is delivered, upon his or her written or oral request, a copy of any or all reports or documents referred to above which have been or may be incorporated by reference into this prospectus but not delivered with this prospectus, excluding exhibits to those reports or documents unless they are specifically incorporated by reference into those documents. You may request a copy of these documents by writing or telephoning us at the following address:</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">NeuroOne Medical Technologies Corporation <BR>7559 Anagram Drive <BR>Eden Prairie, Minnesota 55344 <BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">(952)&#x00a0;426-1383 <BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Attention: Ron McClurg <BR>ronm@n1mtc.com</FONT></P>
		<P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any statements contained in a document incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus (or in any other subsequently filed document which also is incorporated by reference in this prospectus) modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed to constitute a part of this prospectus except as so modified or superseded.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:24pt;text-align:center;margin-top:24pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">Up to $1</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">4</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">,500,000</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:24pt;text-align:center;margin-top:24pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:18pt;">NEUROONE MEDICAL TECHNOLOGIES CORPORATION</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:24pt;text-align:center;margin-top:24pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">Common Stock</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:24pt;text-align:center;margin-top:24pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">_________________________________</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">PROSPECTUS SUPPLEMENT</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">_________________________________</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:24pt;text-align:center;margin-top:24pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><IMG ALT="" SRC="tjonestrading_logo.jpg" STYLE="width:189.44px;max-width:100%;"></FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-bottom:24pt;margin-top:24pt;text-align:center;margin-top:24pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">December&#x00a0;21, 2022</FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>


</DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tneuro_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tneuro_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M?V\$,E>.N)'_ ./*?7K"6VWF\LO[&>:.F!HE=:?[RPZ,)M'YQ?)3:4D?^_\
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M@'@!T!'LCZD7KWOW7NO>_=>Z.7_+Q_[+@^+_ /XE_:O_ +E'V,?;[_DM6?\
MS67_ "]03]YW_IW^_?\ 2NG_ , ZWW?>;_7SF]);?/\ QY.\/_#6W!_[J:OV
MNVS_ ')B_P":L?\ Q\=(]Q_W'E_YIO\ \=/6J1[SZZP3Z][]U[KWOW7NN<4L
MD,D<T,CPS0NDL4L3M')%)&P=)(W0@JRD @@@@CWIE#"AR#@@\".MJQ0@@T(R
M".(/1XNEOGKW!UG+2XS=M4_9VTHQ'"U#N"K9=Q44*@)JQFYS%/,Q  _;K5JE
M(&E3'<M[B[F;VGV[>P7MQ]-+DZHQ^FQ_I)4 ?:NGYUX=2;RY[J;ALQ"7!^IB
M%!1S^HH^3Y)^QM7R(X]7$=+_ "*ZN[VQAJMDYP+EZ>%)<IM/+K'0;EQ6KAFF
MH/+*LT0) ^XI9)XKD N&NHQRYEY.ON57TW2=A-%E2K1O]AH*'^BP!^5,]9"<
MN<VV7-":K9^X"K1-VR)]HJ:CYJ2/GT.?L+=";KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOG
M;^_=>Z%GI'NSL/X]]D;>[2ZQS<V%W+@*@:DN[XW.8J62-LEMW/T2NBU-#5I$
M$GA8@@A9(VCFCCD3W7NMS[X@?+SKCY@]:1;TV;(,3N;#BCH>P=AU=2D^7V;G
M*F*5HT=PD7W%!5?;2OCJ]459DC=66.>*>&+W7NC8^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0G:7_,L
MNQ?_  Q-W?\ O/Y#W[KW7S\O?NO=>]^Z]U[W[KW6WW_)R_[(BVM_X??87_N\
M/OW7NK3??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%I^47RRZ;^(W7U3O[MK<"TSRI/
M%MC:&,,%5N_>N5BCU+B]NXIYH=7)7S54S14\ 8--*@*W#W,G-%IRK;F>Z:G'
M0@R\C>BC_"30#S(ZE7VD]F]]]Z=S7;=EAU4(,]S)5;:UC)IKE< T_HHH9W.$
M4FO6G5\T_P"8IWG\S<U/0Y^ODV1U)2U2RX#J3;M?,<(A@E66FR6ZZ\1TLF8K
MP8T82U"+#"RWI:> M(7Q+YQ]P+WF]RKGPX >V!3VX-:N<:V^W _"!DGN#[#?
M=@Y>]BH%DMT%WN3*1-N,R#Q>X4*0K5A!'DBBDNP-))' 4 @7L"=9)=>]^Z]U
M[W[KW7O?NO=>]^Z]T<O^7C_V7!\7_P#Q+^U?_<H^QC[??\EJS_YK+_EZ@G[S
MO_3O]^_Z5T_^ =;[OO-_KYS>DMOG_CR=X?\ AK;@_P#=35^UVV?[DQ?\U8_^
M/CI'N/\ N/+_ ,TW_P".GK5(]Y]=8)]>]^Z]U[W[KW7O?NO=>]^Z]TZX3.9G
M;66H,]M[*5^$S6+J%JL=E<75345?15" @2TU53O&ZFS$&QY!(-P2/;%U:Q7L
M;13*KHPHRL RL/F#T_:W4EE(LL+,CJ:JRDA@?D1U<7\7_GWCMTOC]B=X5-%A
M-Q2>*EQ._=,5%@LU*2L<=/N*-=$=#4L2+5*A:9^=8@(7R8X\\^TKV :[VL,\
M>2\&6=!QJGFZ_P!'XAY:LTR'Y)]U$ORMKN95),!9\*CGT?R5OG\)_HXK9^""
M 0001<$<@@_0@^X,ZFKKOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\[?W[KW7O?NO=#K\=OD3V7\8N
MR\3V=UCEC19.B(I<QAZHRR8'=F!DECDKMO;AH8Y(_-3S>,%6!62*14FA=)41
MQ[KW6Z'\6_E!UO\ *_J_&=C]?UR1U*I3T6\-I5,\;YS9.Y# )*K#96)1&60D
M,U)5JBQU$0#I9@Z)[KW1D/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2$[2_P"99=B_^&)N[_WG\A[]U[KY^7OW
M7NO>_=>Z][]U[K;[_DY?]D1;6_\ #[["_P#=X??NO=6F^_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NB._.;YT=;_"3KJ'<&XH5W1V'N=:NGZZZXI:T4=;N&KI?$M7E,G6"&I-
M'BZ0SH:FJ,;LS,L42/(WI!O.G.EOR;;^))WRO411 T+D<23FBBN33Y"I/60'
MW??N^;K[^[H;6U/T]G!I:]OF74D"M72B+5?$F>AT)4"@+,0HSI0=]_(#M3Y+
M=CYCM+MW<M1N+<N5=XJ6$:X,-MS#K43U%%MO;.,,DJTE!3?<.(859F)9I)7E
MFDDE?#G?=^NN8[AKF[<LYX#@J+4D*H\E%<>?F234]=[?;CVVV?VIVN+:-D@$
M,$="QP99Y=(#2S/0%Y'TC4V ,*H5%50#'LGZ'?7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T<O^7C_P!EP?%__P 2_M7_ -RC[&/M]_R6K/\ YK+_ )>H)^\[_P!.
M_P!^_P"E=/\ X!UON^\W^OG-Z2V^?^/)WA_X:VX/_=35^UVV?[DQ?\U8_P#C
MXZ1[C_N/+_S3?_CIZU2/>?76"?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M5F/P\^:]7LBHQG5_;N4DJ]D2M'0[;W;72/+5[1E=[04&8J7+-)C"6TI*UVI>
M 2:<6AA'W&]LEW,-?;<M)A5I(5P)1YE1Y/ZC\?\ IOBFCV]]R6VXK8[@U83V
MQRL:F(^08^:>A_!_I?ANKBEBGBCG@DCFAFC26&:)UDBEBD4/')'(A(96!!!!
M((-Q[QF92IH<$8(/$'K(\$,*C(/ ]9/>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\[?W[KW7O?NO=>]^Z]T9'
MXL_*'L;XF]I8[LKK^H2IB9%QN[MIUTTL>$WGMN29):K#9+QAS'("@EI*M%9Z
M>95<!T,D4GNO=;H?QT^0W77R=ZNP7:G6^1\^,R:?;9?"U4M-_'-IY^!(VR.V
M]PTM/-,(JF$R*R\E98GCGB+12(Q]U[H=/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA.TO\ F678O_AB;N_]Y_(>_=>Z
M^?E[]U[KWOW7NO>_=>ZV^_Y.7_9$6UO_  ^^PO\ W>'W[KW5IOOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z+)\M_E-U_\ $/IK/]L;[G2IG@5L7LS:D53'!E-[;OJH)7Q>W\=J#E5/
MB::LJ-#B"GBDE*L55&#O-/,L'*MHUU.>&(TK1I)#P4?X2?( GJ5_9CVAW+WK
MWV'9MN! ;]2YN"I,=K;*0'E?]H5%J-<A5016HT5^_>^>R/DIVEN;MSM/-RYC
M<VXJIS#3HTJ8C;F%BFF?%;6VU0RRS?;8^B28I!$&9F)>:9Y:B6663"G?=\N.
M8KI[NY;4[G _"BYHJCR5:X'VDU))/T+^V_MSM7M5L\&R[/$(H(5RQIXD\I #
MS2L -<LA%6. !1$"HJJH->R?H==>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M='+_ )>/_9<'Q?\ _$O[5_\ <H^QC[??\EJS_P":R_Y>H)^\[_T[_?O^E=/_
M (!UON^\W^OG-Z2V^?\ CR=X?^&MN#_W4U?M=MG^Y,7_ #5C_P"/CI'N/^X\
MO_--_P#CIZU2/>?76"?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=6
ML? _Y8R8RJQ71G8V2+8NK=*'KK/UTR#^&5;LJTVSZV:0+>"9F*X]V<F.0K3
M&-XA% ?NMR )E?=;)>X=UQ&H^(><@'J/QCS%6X@UG7VNY\,3+M=XW:>VWD8_
M"?*,GT/X/0T7@12XCWCGUD'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7SM_?NO=>]^Z]U[W[KW7O?NO=&O\ A_\
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MNO=67>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUH/Y\'_,S?C_ /\
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M5@MOX.AI\9B,3CJ1!'3T=!0TD<4<<:@<*JCFY/))]Y5VUM'9QK%$JHB *JJ
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M_$+!8ZG7RI0U^].W<AF9ICIF$%35XC![$P*Q<M&7@2MEX5@)?4&22+'[HR
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ML6R&CW+Z.-#X:4=R/7.E3\FZSI^X#[=#F[G)MVG35!M%N9P2NI/J[C5! #7
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M?NO=>]^Z]U?!_+>W*<QT%6X.5P9=H[YSF-ABU79:#)TN,S\,EOP&GR=4 /\
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MK23K_P"4?_,>R==69*OZ >JKLA5U%=6U,G;71GDJ*NKF>HJ9WT]EJ+N\C,;
M<GWAQ)[6<PRL7:UJ6))/CVV234_Z-UWSMOOH^UMG&D,6\!4151%&W;M154!0
M/]P?("G43_AH'^8G_P!X\_\ L6NC?_MF>Z?ZU&__ /*+_P!5[;_K=T__ ,&U
M[8?]'K_NG;M_VP]>_P"&@?YB?_>//_L6NC?_ +9GOW^M1O\ _P HO_5>V_ZW
M=>_X-KVP_P"CU_W3MV_[8>O?\- _S$_^\>?_ &+71O\ ]LSW[_6HW_\ Y1?^
MJ]M_UNZ]_P &U[8?]'K_ +IV[?\ ;#U[_AH'^8G_ -X\_P#L6NC?_MF>_?ZU
M&_\ _*+_ -5[;_K=U[_@VO;#_H]?]T[=O^V'JX7^3W\"^^_C%V5W!V)\@NMX
M]B9'([)P6SMCR-NK8FZI,C2Y3.2YG=@C;9FY]Q&G\3;=Q8;[@0^3R_MEM#Z9
M:]IN2+[ENXN)[^'PV:-(X^^-Z@L6?^S=Z4TKQI7RX'K"#[[WWB^7/=K:]LVS
MEJ^-VD=U-<W8^GN[<(T<0BAK]5!!JJ)IOAU::=U*BM_/N<NN<'7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2+
M[(VNN]^OM\;.9%?^]&TMPX&,,54+-E<554=/(&<@*4>965B18@&_'LSV6_.U
MWD%R/]"ECD_)7!/\AT7;O9#<K6:W/^BQ2)_O2D?Y>J"_]D3^57_/K/\ U]^N
M?_LO]Y9_ZZNP_P#*5_U0N/\ K3UBM_K8;[_RC?\ 5:W_ .MO7O\ 9$_E5_SZ
MS_U]^N?_ ++_ '[_ %U=A_Y2O^J%Q_UIZ]_K8;[_ ,HW_5:W_P"MO7O]D3^5
M7_/K/_7WZY_^R_W[_75V'_E*_P"J%Q_UIZ]_K8;[_P HW_5:W_ZV]>_V1/Y5
M?\^L_P#7WZY_^R_W[_75V'_E*_ZH7'_6GKW^MAOO_*-_U6M_^MO7O]D3^57_
M #ZS_P!??KG_ .R_W[_75V'_ )2O^J%Q_P!:>O?ZV&^_\HW_ %6M_P#K;U9'
M\">FNW>F<9V9B>S]K_W:I<Q7[6R.WA_'=O9G[RHAI\[39LZ<!F<L(O&JT7,H
MC+:_3JTG3"_NQS)MW,LEM)8R^(4659.R1* E"O\ :(E:]W"M*>5<S'[6<O;A
MR['<1WL7AAVC:/OC>IHX;^S=J4HO&E:^=,6"^XAZE?H@O\TS_MW;\PO_ !!^
M[_\ W'C]R)[2?\K-MG_/9#_QX= /W1_Y5S<_^>*X_P"K3=?-1]]7.N5?7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=?0\_DB=_R=^?R\>GSDLA_$-S].29;HW<C
MO/)/-$-B&E?9\<QE&H$;<R^&!N6!(-C_ &5YB>_G+7]6N9[H*NF.YTW<>* B
M:I>E/+Q5D'Y==-?8[F3^LW+5J[,&D@4VLO=J(:#M757-6CT,:_Q=6V>X:ZEO
MKWOW7NBF_-_Y6;6^%WQF[,[_ -S1P5]3M?$FAV9MR:9X#N[L'-:J#9VV5DBC
MF=8YZN19*R9(Y##2PSSZ6$1'L8\@\GS<][M;[9#4>*]9'I7PX5[I'R0#10:"
MHU-1:U/03YXYKAY)VNXW*;(B3L2I'B2MVQI4!B-3D FATBK' /7S1.S^R][=
MR=A[S[4['SU9N;?._MQ9/=&Y\W7.7FK<IE*AZB;Q)<K%!$&$--3QA8X88TAB
M58T51U=V;:+?8+6*RM$"0PHL<:CR513/J3Q8G+,23DGKE?O>\W',-W+?73%Y
M9G:1V)/%CP%2:*HHJKP50%& .D)[,NBOKWOW7NO>_=>Z][]U[J50T-;DZVCQ
MN-HZK(9'(55/0T%!0T\M76UU;5RI3TM'1TM.DDDLLLDBI'&BLS,P !)]TEE6
M!2[D*J@LS,0%50*DDG  &23PZ<AA>X=8XU+,Q"JJ@LS,QH  *DDDT &2>MC_
M .$7_"=ON'N'%8;L+Y:;KR'0FSLI%'6TG6V!I*+(=QU]#+J,39J7)15>-V\T
MB%9$BJ(<I5+<QU-)32 J,5^?_O/V6RNUMLD:W<BFAN)"RVP/]$*5>3TJ"B^:
MLPSUE/R']V.ZW6-;C?)6M5:I%O%H:XIY%F(=$KQTT<T/=I-0-@OJG^2I_+;Z
MHI$CI_CKB=_9/QTZ56=[6S^Y-^5=8:8.$D?$Y3*#$0LQD9I/L\;3![@,"%0+
MC1O/OOS5O1[KYXES1;=4@ K\T4.>&-3&GEQ-<D-G]DN5]E!T6$4A-*M<%[@F
ME> E9U7CG2JUQ6M!0<LA_+/_ )?63I)J*I^&_P =XX9P%=\?U?MC$U:@&_[.
M0Q5!13QG_&.13[#\?NIS+$=0W.^QZW,K#]C,1_+H]?VSY=<4.V6'Y6L(/[0@
M/5>/R+_X3P?"/M7'Y*LZ8DWE\<-X5#55315.WLQD]^;'^]J$=A_$MF[TRM74
M?;B5@ZT^-R^,5!=$"H%59-Y7^\US#LK*M\8[Z(4!615BETBG"2)1W4QJ='KQ
M-3U&W,WW;N7MZ1C9K)92DLP>)VDCU&O&.5F&@$UTQF/ H"!UJB_.7^6U\EO@
M/N2"E[8V]!G.O,WD*FCV=V_L\5>1V+N%HVEDI\?75$D$4N*R;PQF4XW()$[!
M)6IGJ88FF]YE>WGNMM7N1$39N4G109;:6@E3U*T-'0'&M>&-04D#K#WW"]J-
MU]NI*W2B6W8D1W,08Q'- 'J*QN10Z6P<A&?22" ^Y+ZC+KWOW7NO>_=>Z][]
MU[I3[)WINKKC>&V-_P"Q\Y7;:WCLS.XO<VU]P8UUCKL/G<+60U^,R%,9$D0M
M%+ K:75T8#2ZLI(*/<=O@W:"2UN4$D4J-'(C<&1A0C%#P/$4(X@@]+MLW.?9
MKB.ZM7,<L3AXW7BK*:@YJ#\P0014$$$CKZ77P'^6NW_FQ\6^M.^<0E+19O,X
M]\%V'M^ED#KM?LC;PCHMV8<*69EA>4I74'D];4=932, 7('*+W$Y,EY"W>?;
M9*E4;5"Y%/$A?N1OMIAJ<&##RZZI<A<W1<\;5!N45 9%I(E:^',O:ZY P&!H
M:"JT/GT<?V".AAU\[?W[KW7O?NO=>]^Z]UM6_P C3_LDSL/_ ,6)W;_[[7J3
MW[KW5S?OW7NO>_=>Z0_9/6VR.WMD;AZZ[%V]0;HV=NB@?'YC#Y!"8Y8R5DAJ
M:::-DD@J8)$2:FJ87CEAEC22-U=58>Z]UIM_.KX/[W^'78<E.T5?G^H=T5]4
MW7._'02B>$:ZC^Z^YI:>"".#+TL8.M0D:5,:&H@%A-%![KW1$_?NO=>]^Z]U
M[W[KW5\O\KS^91-L>JP7QO\ D%N)#L.<0XOK#L'-U+:]EU3/'#0[-W'7S:A_
M!Y-6BAJYF'V+ 0NWV;(:/W7NMF($, RD$$ @@W!!Y!!'OW7NN_?NO=>]^Z]U
M[W[KW2$[2_YEEV+_ .&)N[_WG\A[]U[KY^7OW7NO>_=>Z][]U[K;[_DY?]D1
M;6_\/OL+_P!WA]^Z]U:;[]U[J%DLA1XG'U^5R$RTU!C**JR%=4/?1!1T4#U-
M3,UK\*D;,?\ 6]^Z]UH%=O\ 8F2[<[4[%[0RYF_B&_MZ;CW9-%,^MJ1,WE:J
MNIL>AU,!'313)3Q(ITJD:JO 'OW7N@Y]^Z]U[W[KW5XO\D3H6DWCV[OSOC.T
M25%#U-B*7;^T?N(=41WIO2&NBK<G2RDD>2@Q=%/"ZD<?Q:-P05'OW7NMH/W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:_?\\_I&EJ]M=3_(;&
M4=LGB,I+U7NRHB34U1A\I#DMR;2GJ2HNJ4M329*+6>"V01;@Z0?=>ZUN_?NO
M=>]^Z]T9WX8=H2].?*GHKL!9_MJ/&=AX/%YN;64";9W5*VT]T,?K>V/S=2P4
M\$@<CZCW7NMZOW[KW7O?NO=>]^Z]T5KYO_\ 9'OR9_\ $)=B_P#O,Y#W[KW6
MBY[]U[KWOW7NO>_=>ZV^_P"3E_V1%M;_ ,/OL+_W>'W[KW5IOOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM8_\ GMY#R=R=&XKPZ?L^LLWD//Y+^3^)
M[IGIO#XM MH_A.K5J-_):PTW/NO=43^_=>Z][]U[HVGP._[+*^-7_B7MG_\
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M8(5PSA83/J5M;%5U\^Z]U9+_ ,.O_ +_ )_W_P"PM[I_^US[]U[KW_#K_P
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M_6SKW_#D/P!_[S,^-7_HXMC_ /UY]^_UK^9/^C7?_P#9+-_T!U[_ %RN7?\
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MCKW][-J_\]-M_P#\_.._^J??OI9?X&_WD_YNO>,G\0_:.O?WLVK_ ,]-M_\
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MOJ ?Z4MA?\]'0?\ ,O\ _2E_G/\ F O^>C^G_ ?_ &KWR._=D_\  ?[7P?\
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M%_[O#[]U[JTWW[KW57?\X?.'$_!W>M )O'_>?>?7>#*:I1]P*?<])N7P@1D
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M_=>Z&GXV["HNU?D3T)U?DXGGQO9'=/5NPLA#%_G)J+>&^<%MZKBCN1ZFCR+
M?XGV'^;=Q?9]JO;N,T:"TN9E/HT<+N#^U>A'R?8)NF[V-K*-237EM$X/FLDR
M(1^8/7U/(XXX8XXHHTBBB18XHHU5(XXT4*D<:*  H    L![Y $UR>NMH%.N
M?O77NO>_=>Z][]U[KWOW7NJ/O^%">QL5NK^7%NS<5=#&]=UGVCU;O#"S-Z9(
M:W)YY^O:D1L(W)#4N^)PR74&P8DE0#/WW:=P>SYJBB4T$\%Q$X]56,S#_C40
MZ@K[QMC'=\JSR. 3#+;R(?X6,RPDC_:RL/L/6@Q[Z1=<Y.O>_=>Z][]U[KWO
MW7NO>_=>ZOY_X3?U$$/\P'<D<LL<<E7\<.Q:>F1V"M/.N\>LZIHH@?JPCII'
ML/[*$_CWC7]ZA2>6XB/*_A)^0\&X'^$]9(_=;(',4WSL)O\ J_;'K>O]\\^L
M_P#HB'\SWL3_ $6?R^OESNY,BV)J6Z5W9M+'Y&.L6@J*7+=BP1]>8=Z.K:2(
MI4&JW3"M.8V$AD*"/]PK[D+VHVS]\<R;;!IUCZN*1ETZ@4A;QFJ*&HTQG57%
M*UQ7H">Y^Y?NCE[<9]?AD6DRH^K01)(AB2AJ*,7<!:9U4 S3KYHWOJ]URJZ]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMF;_9JLQ_HQ_TA_WQSOVG_0.[
M_HS\O\9J]'^D'_9O?]E>_C]OOM/\4^^_9^^O]QJYU:_3[Q'_ *F1_5?3>"FK
M^NOBT\-?]Q_W?]=H^'^ST9T_#3RIUEY_7*7Z?ZCZF33_ %+TU\5J?5_6?1Z_
MB_M?$[=7QZL5KCJOGW@OUFIU[W[KW7O?NO=;5O\ (T_[),[#_P#%B=V_^^UZ
MD]^Z]U<W[]U[KWOW7NO>_=>Z][]U[KWOW7N@:[\Z'Z\^2/6&X>J>R\7]_@<Y
M")*6NIQ"F9VYF:=7.-W'MZMFAG\%93,Y*/I971GAE62&22-_=>ZTQ/EM\2>R
M_B'V74;'WQ3G(X'(FIK=B;[HJ:6'![TP<,JK]S3:FE\%;!Y8TR&/>1G@=E(:
M2"2">7W7NBK^_=>Z][]U[K)#-+3RQ3P2R03P2)-#-"[1RPRQL'CEBD0J592H
M*L"""+CW[KW6T1_+"_F2?Z8:;&?'[OK/4T?:F/IH:/8&],G4>*3LNB@C95PF
M7GD4(<Y D8T2EPU>G)!JD=JCW7NKO/?NO=(3M+_F678O_AB;N_\ >?R'OW7N
MOGY>_=>Z][]U[KWOW7NMOO\ DY?]D1;6_P##[["_]WA]^Z]U:;[]U[JG/^=_
MD:BB^(FT::$1F/,=];.QU7K4LPIXMD=E993"0RV;RXN($D'TEA:Y!'NO=:H?
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NMQG^43EAD?@CU91ZK_P'.]E8DC1HTF;
ML/<F<TZO[7_%ZOJ_QM^/?NO=67^_=>Z][]U[HK7S?_[(]^3/_B$NQ?\ WF<A
M[]U[K1<]^Z]U[W[KW7O?NO=;??\ )R_[(BVM_P"'WV%_[O#[]U[JTWW[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6K[_ #U_^9]]-_\ B(9O_>SS_OW7
MNJ.??NO=>]^Z]T;3X'?]EE?&K_Q+VS__ '91^_=>ZWE/?NO=>]^Z]U[W[KW7
MO?NO=5'_ ,ZG_LC6#_Q+VQ__ '6[I]^Z]UJ3^_=>Z][]U[KWOW7NM]?XQXR/
M"_&SX]8>*5YHL3T=U-C(YI %DFCH-A8"E25U7@%A%<@?U]^Z]T./OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM2W^==4I/\Q\?$J2JU%TWLBFD:1-*2
M.^:WA6!X&N=2Z:M5+<>I6'X]^Z]U43[]U[KWOW7NKT?Y$N(AF[L[MSS+#Y\;
MU9C,1&S0*U0(<WNW'UDZQ5)]2(6V_'Y$'#D(3^@>_=>ZV=_?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T6_YC4T-7\2/D
M_%4)Y$7X^]Q5*KJ=;34?7VX*RF>Z,I],D"-;Z&UB""1[]U[K1']^Z]U[W[KW
M7O?NO=;V/PQK?O\ XB?&*?Q^+1T)U/1:=?DO_#=CX3'>35H3]?VNNUN-5KFU
MS[KW1E_?NO=>]^Z]U05\L=L-M7O_ +%IA#XJ?+Y6+<]*X%DJ%W)1T^6JYD_U
MJJIJ(V_VI&_')BW?8? NI!ZG4/\ ;"O^&O73GV0W@;URO8O6K11FW8>:F!FB
M4'_:*I'R(Z+I[*>I7Z][]U[KWOW7NO>_=>Z56QMV9#8F\=L[RQ9/WVV\U09:
M*,.8UJ5I*A))Z*1P&LD\8>&3@W5R/;]M.;619%XJ0?V>7Y]$O,FQQ<RV%QM\
MWP7$3Q$TKI+*0&'S4T8?,#K8\VYG\7NK 8;<N%J%J\3GL919;'5"_P"[*2NI
MXZB'6OU5@)+.AL58%2 01[EV*59U#KD, 1]AZY,[KMDVRW4MG<+IEAD>*1?1
MD8J?M&,'@1D=/7MSHOZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NM3;_A2[\IJ1:'ICX=;<R$K5\M6.\.S8J:>>*."B
MABR^U^N,)6&']N;SR39?(3TLK7C-+0SZ#Y(G&97W4>3V:2ZWR51I ^D@J 26
M.F25A7(TC0H(&0SBN".L0?O3\WB.&VV2)CJ<BZGH6 \-=21*:"C!FUM2O:8T
M)&5(U(/>:W6%O7O?NO=>]^Z]U[W[KW7O?NO=?0__ )'_ %/4=4?RVNAER$$5
M/E^QANWMC(K$K@24^]-S9&;:\[O(D19GP=%BV8Z; DJI955VYA^_N\KO/-5Z
M4)*PF.W%?6&-5?S./$UT^630XZZ:^Q>T-LW*UBCTU2H]P:5^&>1I$X@9\-EK
M\\ D9ZMI]PWU+?1!?YIG_;NWYA?^(/W?_P"X\?N1/:3_ )6;;/\ GLA_X\.@
M'[H_\JYN?_/%<?\ 5INOFH^^KG7*OKWOW7NO>_=>Z][]U[KWOW7NCU_RQ<%3
M;B_F%?#G'U=)-614_?\ UWG4A@,ZNE3M?.4^YJ*K8TY5M$$V(CGD!])2-@]T
MU#W''N_=-9\L;FZD FTE2IIPE'AD9]0Y \ZG&>I*]G;-+[F?;DD&H"Y60"I'
M=$K2J<4X,@/H:4.*]?2]]\INNHW7O?NO=>]^Z]U[W[KW7O?NO=5*_P ]#_MU
MC\H__*)?_!%=1^YH^[U_RN&W_P#45_VA7/4-_> _Y5&__P"H7_M-MNOG@^^G
M'7-/KWOW7NO>_=>Z][]U[KWOW7NKVO\ A.O_ -O$J?\ \0?V=_[D;8]XY_>B
M_P"59'_/9!_QV7K(S[K_ /RL;_\ /%-_U=@ZWSO?.OKH)U35_/RR[XW^61W/
M1KY;;@W7T]B)/&^E"D/:6U<\/.O]I-6$6P_U6D_CW.7W<HO$YMM#_ ETW_9M
M*O\ S]U"OWA7T<I7@_B:V'_9U"W^3KY]GOI=US9Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NK(?X^?\ 98_X=K-O^&WOX!I\9M;_ (=Y_O1HU7^E_5J_
MKZ?\?<4>!_NXU?\ 2=U?^0SHZEKQ?]T]/^D#I_\ (GU=+_WRVZZ;=>]^Z]U[
MW[KW6U;_ "-/^R3.P_\ Q8G=O_OM>I/?NO=7-^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7N@'^1_QTZX^4/5V8ZL[*Q\DV-KB*[#9FA*19O:FX:>*:/';BP52
MZN$GA\S*R.&CFC=X95:-V4^Z]UIB_*CXK]F?$KLRLZ]["H_N**H^XKMF;SH:
M>5-O[WV^DHCCRF+DD,GCFC\B)74+NTE-(P5B\;PS2^Z]T6GW[KW7O?NO=2*2
MKJJ"JIJZAJ:BCK:.HAJZ.LI)I*>JI*JGD6:GJ::HA9'CDC= R.I!4@$$$>_=
M>ZVMOY9O\QRD^1&+QW2'<5?!1=XX'%:<)GJB1(:7M?$8N!1+5J78!<[!%&9:
MZF7BH17JX  L\4'NO=6G]I?\RR[%_P##$W=_[S^0]^Z]U\_+W[KW7O?NO=>]
M^Z]UM]_R<O\ LB+:W_A]]A?^[P^_=>ZM-]^Z]U3I_.^QL]=\0]IU4+Q+'AN^
M=G9*J$C.'D@EV5V1AU2 +&X+^7*QL0Q4:58WN I]U[K5"]^Z]U[W[KW7O?NO
M=;1'2/\ )Z^+&\NF>I-X;QJ.T/[V[LZTV+N;<XQ>\L=3XQ-P9_;&+RV8CQT!
MVW,4@6HJY%A4NY" 78GGW[KW0H?\,K?#7_COV]_Z'&-_^Q;W[KW7O^&5OAK_
M ,=^WO\ T.,;_P#8M[]U[KW_  RM\-?^._;W_H<8W_[%O?NO=>_X96^&O_'?
MM[_T.,;_ /8M[]U[KW_#*WPU_P"._;W_ *'&-_\ L6]^Z]U[_AE;X:_\=^WO
M_0XQO_V+>_=>Z]_PRM\-?^._;W_H<8W_ .Q;W[KW7O\ AE;X:_\ '?M[_P!#
MC&__ &+>_=>Z]_PRM\-?^._;W_H<8W_[%O?NO=>_X96^&O\ QW[>_P#0XQO_
M -BWOW7NO?\ #*WPU_X[]O?^AQC?_L6]^Z]U[_AE;X:_\=^WO_0XQO\ ]BWO
MW7NC[?'+XY]??%SKK_1?UG+N*7; SV3W$G]YLK%E\A'79>.D2KCCJH:+'J(O
M\C5E01\,S&YO[]U[H>O?NO=>]^Z]T5KYO_\ 9'OR9_\ $)=B_P#O,Y#W[KW6
MBY[]U[KWOW7NO>_=>ZV^_P"3E_V1%M;_ ,/OL+_W>'W[KW5IOOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM6+^>?DIY?D]UAAV2(4U#T-A<E"X5_.T^
M5[![%I:A)&,A4HJX:(H H(+-<D$!?=>ZI4]^Z]U[W[KW1M/@=_V65\:O_$O;
M/_\ =E'[]U[K>4]^Z]U[W[KW7O?NO=>]^Z]U4?\ SJ?^R-8/_$O;'_\ =;NG
MW[KW6I/[]U[KWOW7NO>_=>ZW[.@$>/H?I..1&CDCZCZW1T=2KHZ[-PRLCJP!
M!!%B#[]U[H7/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:H?\[['U%+
M\N=I5<JCP9/HK:-13.H?3:GWEV'12Q.S(HUJU/J*J6LKH2038>Z]U3G[]U[K
MWOW7NKM_Y%^XTHOD5VMM:21T_O!T[/E84M'X9JC;F\=L0A&8^O6(\_*R >DJ
MKZN0OOW7NMI'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=%7^<6=I]N?#OY,Y"JDBCBJ.E>P<$K3-I0U&Z=NUVV:.,$NG
MK>;+HL8ORQ L?H?=>ZT7_?NO=>]^Z]U[W[KW6^5\4<3+@?B[\<,-40Q4]5C.
MB.I**MBA"B-:Z#8. 2N8%56Y:8.S-:[$DGDGW[KW0_>_=>Z][]U[JK#^8GLA
MHLEL'L6G@_:JZ2LV=EIQ8!:BCDES&$5@/JTB5-=ZOK:$#Z >P3S;;4*3#SJA
M_+(_R_LZS1^ZGS$'AO=I<Y5ENHA_18"*3\@5CQZL3U6=[!O67_7O?NO=>]^Z
M]U[W[KW7O?NO=6H? GNN&HH*KI;<%8J5E$U9F-C/,X'W5%*TE9F\%$687>%R
M];"@!+)).>%B ]C?E?<:@VSG(J4^8XD?EQ_;Z=86?>:]O&BE7F&U6J/IBO !
M\+BB1RGY,*1L< $)Q+'JS#V,>L0NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z!GY"]\=>_&7IGL#O/M++1XG9G7FWZK-5Y,L
M$=9EJP 4^&VWAHZB2)9<ADZR:"@H(=0USU"*2 20><M\O77-=]#M]FI>69PB
MC-%'%F:G!44%F/DH)Z)^8-]MN6;.6_O'"10H79CY^04>K,2%4<68@#)Z^9G\
MF?D%OCY4=[]E]^]B2H=S]C[BGS$U#!*\M%@L5#%#CMO;:QKR*C&FQM!1TU%
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MC_I=VBU@"39<BC,>/P "3_K>_=>ZWD_?NO=>]^Z]U[W[KW7O?NO=5'_SJ?\
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M<N:U732/[R"ZQ[Z][]U[KWOW7NO>_=>Z][]U[K8'_P"$[?Q<G[=^7V6[]S=
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M,'KI?U[W[KW7O?NO=>]^Z]U[W[KW52O\]#_MUC\H_P#RB7_P174?N:/N]?\
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M?>_HMP5FB\"62BN4.I2@&5S^(];5G_0.M_+N_P"./>/_ *,ZF_\ L7]X=?\
M!-<T_P =M_V3K_T%UE[_ ,#CRM_OB;_LHE_S]>_Z!UOY=W_''O'_ -&=3?\
MV+^_?\$US3_';?\ 9.O_ $%U[_@<>5O]\3?]E$O^?KW_ $#K?R[O^./>/_HS
MJ;_[%_?O^":YI_CMO^R=?^@NO?\  X\K?[XF_P"RB7_/U[_H'6_EW?\ ''O'
M_P!&=3?_ &+^_?\ !-<T_P =M_V3K_T%U[_@<>5O]\3?]E$O^?KW_0.M_+N_
MXX]X_P#HSJ;_ .Q?W[_@FN:?X[;_ +)U_P"@NO?\#CRM_OB;_LHE_P _7O\
MH'6_EW?\<>\?_1G4W_V+^_?\$US3_';?]DZ_]!=>_P"!QY6_WQ-_V42_Y^O?
M] ZW\N[_ (X]X_\ HSJ;_P"Q?W[_ ()KFG^.V_[)U_Z"Z]_P./*W^^)O^RB7
M_/U[_H'6_EW?\<>\?_1G4W_V+^_?\$US3_';?]DZ_P#077O^!QY6_P!\3?\
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M\Y %!!(U'Z*WOW7NMNCW[KW7O?NO=>]^Z]U[W[KW51_\ZG_LC6#_ ,2]L?\
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M82GXAE3\Q_D/#^?EU)7M3SZ_M[N\=V:F!_TKE!^*%B*L!YLAHZ^9H5J QZH
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M+V">LT.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z&?XZ_\SUZG_\
M#YP'_N;'[,=H_P!RHO\ 3K_AZC_W6_Y5O<O^>.?_ (X>MAGW*_7*_H.NX/\
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MW7O?NO=>]^Z]U[W[KW0S_'7_ )GKU/\ ^'S@/_<V/V8[1_N5%_IU_P /4?\
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MMV;BS&XJR-6^H2IS%96. ?S9O?NO=)/W[KW7O?NO=>]^Z]U[W[KW5LG\N/\
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M=WEFJ</$JEZB@0$7B&N6$"_KB!:,";SR\8*RP"J\2OFOV>H_F/LX9Q^S_O\
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MX#_E4;__ *A?^TVVZ^>#[Z<=<T^O>_=>Z][]U[KWOW7NO>_=>ZO:_P"$Z_\
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M'&BJJJH   ]^Z]U/]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= #\E/C?UO\
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M-)'%%&\LLKK'%%&K/))([!4CC1026)(  %R?>F8**G &23P ZLB&0A5!))
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M53#?5)4IR7DBPN.BCS,:):[-48N  <WMS[]U[HC6;P&=VSD)<3N/"Y?;^5@
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M^QYZ9C&5-!L' Y&*.%F#,&3*Y3&2H1S$WT]X]\W_ 'F]CV(&/;P]]*.&BL4
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M_P#E.L_^RF'_ *#Z]_4C>O\ HWWO_9+/_P!:^O?[+)\DO^\>^\/_ $4^_?\
MZP>_?URV?_E.L_\ LIA_Z#Z]_4C>O^C?>_\ 9+/_ -:^O?[+)\DO^\>^\/\
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MLQ)))))-22<DDGSZR)50HH, 8 ' #J3[KUOKWOW7NO>_=>ZU-O\ ADKYA?\
M.\Z2_P#0TW-_]@OOW7NO?\,E?,+_ )WG27_H:;F_^P7W[KW7O^&2OF%_SO.D
MO_0TW-_]@OOW7NKOOY:OQ;[)^)'1>Z^N.T:K:U9N#-]LYW>]'+M'*5V6QJX?
M);/V)@:=)ZG(8G#NLXGVW4%D$3*%*$,22%]U[JPOW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U5C_,<_EXXGY7;??L7KN*APO?FU\68*&60PT>.[&P]&KR0[8S]2VA8ZN.
MY7&9"0V0M]O.? 4DIO=>Z>OY2>WL[M+X?XS;&Y\1D,!N+ =E]F8G-87+4LU#
MDL7DJ'<+P5=%6TDZH\<D;H596 ^GOW7NK-/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]TR9W;6W-T4OV.Y=OX3<5#:1?L\[BJ#+4NF4!95^WKX
M*A+,% 86YMS[]U[H$<O\0_BGGI)9\M\;.B:NIGD26>L/5&QX:Z9XT\:&:NI\
M'%,P"@"S.18#C@6]U[J!1_"_XB4!D,'QBZ%<R!0WWG5&R,B!IN1XUR&%J@GZ
MN2MK_F]A[]U[H9=M]<=>;-T_W0V'LS:NB^C^[>U\'@]%P0=/\+H:6U[_ (]^
MZ]TL_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U R>+QF:H:G%YG'4&6QE9&T-7CLG1T]?0U4+"S
M15-)51RQNI_*LI'OW7NB6]B_RWOA3V:T]1FNA=J8.OF9I!D-A293KV6.9R2T
M_P!GLZOPU'(QU&XGIIE)-R-0!'NO=%/W%_)!^)V5J)*G";P[LVL'>ZT%'N?:
M>3QL,9>5RL2YC9%957]:J&>K?A!<%B6/NO=(I?Y%'0HK6D;N7MXX[G32K#LQ
M:T>BPU9 X!XSZN?^ PXX^OJ]^Z]TO=M?R1OB1AY%FS>YNZ-W-_:I<ENK;6,Q
MY 9B-,> V;C*@$@@->J-[7 7W[KW1Q>L_@!\.NI9J:KVCT)LB7)4D@GI\ONV
MGK=_92"I4JPJZ6LWO6;@:"0% 5:G\6GG0%N??NO='!BBB@BCAACCAAAC2***
M)%CBBBC4)'''&@ 55      'OW7NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[I,;JV3LS?>.?#[WVCMC>6(D!$F+W5@,5N''2!N&#T.7I*R(W_-U]^Z]T5?=
M'\N_X3;O\O\ %?CCUY2>994?^Z])D=D6$PLYB_N7D<!XR/[#)I*_V2/?NO=!
M76?RDO@74RK)#TYDL>HC"&&C[.[2>)F#,3*QK]XUSZB& -G"V4<7N3[KW2EP
MG\KCX'X"ICJZ/H#%U4Z"(?[F]Z=E;AIG,4B2AI,?G=YY"F))C&H>$ @E2-)*
MGW7NC(;$^-/QYZQ=9^O^D>K-I5@6)3D\+L;;E+F)! NF'SYD8\U4FFY(+S-R
MS-]6)/NO=#=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z\0"""+@\
M$'D$'Z@CW[KW0+[P^._2F^VEEW%USMV2KF8O+D<732;>R<LIL1+/D<!+C)I6
M%A_G7<'Z$$<>RZXVFVNOCC6OJ.T_M6G4@[#[J\Q<M +:7\X48$<C">,#T"3B
M15_VH'[>BZY_^7SU'D'DEP6X=Z[==_TTYK,9EZ"+GC1%5XV.H/\ CJJF_'TY
MN42\J0/\+.OY@C^8K_/J5ML^])OMJ MS!:3@<6T21.?S60K^Q.F+8?P.DV#V
M%M+>M)V<F5I=L[@H<TV,J=I-0U%1'0U"3+2BMBW'5KJ8"QD\*@'^S[;M>6/I
M95D$E0K T*TX?/4>C/F7[RXYGVJZVZ3;S&UQ \7B+=:U4NI&K28%-!Z:C]O5
MA_L6=8J])O>6 ;=>S]U[72J6B?<FV\[@$K'B,ZTC9C%U6.6J: 21%Q&:C64#
M+>UKCZ^U%G/]+*DM*Z'5J<*Z6!I_+IJ>/QD9.&I2*^E13K6-V#_PF"ZNH51N
MT?E?O[=#,2[P;!ZWV[L18E:.EM E5N'<78WD*.LUY3#%K#I^VA1O)EGN?WMK
MV0_XGM\$8_X=-),2:G/8L%,4QFE#DUQBIMGW4;")?\<O[B4UXPQ1P "@Q1S<
M5-:YJ*U&!3-@74?\A?\ EP=5RX^MR75^ZNW\MC6\D&2[<WYF<O%-+H\9DR&V
MMIC9F%JA8G]NHQDL=SJ"!E4K&N]_>)YIWD,JW*6RMQ6VB1"!6N'?Q)!]H>OE
M7CU)&R_=_P"5]F*,;4W#H/BN97D#&E*L@*Q'[/#H#D $"EJ/7'4?5?3V#BVS
MU-UML3K/;T**B8;8>T\%M/&G0  \E)@Z&A1W-KL[AF8W+$DD^X?W/>+O>I#-
M>32SN>+S2/(W[7)/4M;?MEMM,8AM8HX8U% D2+&H'R"@#H0_9=TNZ][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NH61QN.S%!5XO+T%%E,97P24M=CLC2P5U!6TTHTRT]725,<L<B
M,#9D=2#^1[O'(T3!D)4@U!!((/R(ZJRAP0P!!X@Y!ZK8[I_D\?RZN\GJ:W/_
M !NVGLS-U#32_P >ZDGR75E4E147,U2^)V;58S%5$C,=9:KQ]1ZKM]2UY2V'
MWMYGY> 6&^ED0 #1<:;@4'  S!V _P!*PQU&N^^SO+7,)+3V,*L26+P V[%C
MQ),)3436O<#G/'JLSL/_ (3(?'3+"L?JWY&]Q['FF:1Z1-ZX'9O9%#1%];)'
MX,13]:S21H6 4-4ARJV9RQU>Y9VS[V6[0:1=V5K,!35X;2P,WYLTP!/^EI\O
M+J*=R^ZML\X8VMU=PL:E=?A3(A-:"@2)B!Z%ZD<6KGHL.5_X2^=@0R@83Y@;
M.R$&J4-)E>GLUAY0H8"$B&DW_G02PN6'D&D\ M]?8MB^]S 1W[9(/]+=*W^&
M!>@D_P!TR0?#N:G[;,C_  7)Z:_^@8+MK_O+#KK_ -%MN7_[(_;O_!<6O_1M
ME_[*$_ZU=4_X$V?_ *.:?]DK?];^A5VA_P )>L5%6";?OS'R&0QX)4XW:'2E
M-B*R1==.PE&;S/9>;1"5$J&/^'O8E'UD H2B_P#O<RLM+7;%5OXI;HNOG^%(
M(SZ9U>HIY]&NW_=.@1ZW6Y2.E/ABMEB:M1G4\TPI2N-'H:XH3J=8_P#"<WX"
M;+:.HWQ7=T]PU/[33TNZ=]TNV<*S(J^1::DZ[P>TJU$<@DA\C,P!L&%KD [M
M]Y_F7<,6_P!+:C.8H=;?F9VE'[%'V=#O:ONT\M;>#XZW-R2?]%G* ?("W$./
MM)/SZM'Z3^#OQ#^.?V\O2_QVZKV-DZ6."*+<=)M>BRN\2E-S")MZY\9;+R$'
MU7DK7);U$D\^XAW_ )]WKFC_ '/O;B9:DZ&D81@GC2-=*#\E'4N;'R9M/+7^
MX%I;P&@!:.)0Y"\*O34:5\R>C4^PET)NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:,7_P(
MS?\ VM__ )%XSW[KW3O[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
B=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tjonestrading_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tjonestrading_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M_=>Z][]U[KWOW7NO>_=>ZIX_GJ_]N]=\_P#B0>K_ /WJ(/<I^S7_ "ONW?\
M-&;_ *MMU#'O_P#].PWK_FM;_P#5^/K7N_D8?]O#NO?_  Q>TO\ WCJ_W.GO
M5_RHUS_STP_\>/6-?W=?^GCP?\\4_P#@7K>8]X<=9]]>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4\?SU?^W>N^?_ !(/5_\ [U$'N4_9
MK_E?=N_YHS?]6VZACW__ .G8;U_S6M_^K\?6O=_(P_[>'=>_^&+VE_[QU?[G
M3WJ_Y4:Y_P">F'_CQZQK^[K_ -/'@_YXI_\  O6\Q[PXZS[Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIX_GJ_\ ;O7?/_B0>K__ 'J(
M/<I^S7_*^[=_S1F_ZMMU#'O_ /\ 3L-Z_P":UO\ ]7X^M>[^1A_V\.Z]_P##
M%[2_]XZO]SI[U?\ *C7/_/3#_P >/6-?W=?^GCP?\\4_^!>MYCWAQUGWU[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3/N#<6W]IX;(;BW3G<
M/MK;^)IGK,KG=P9.BPV&QE)$+R560R>1GIJ*BIHQRSR.JC\GV[##-<2I!;Q-
M),QHJ("S$^@ J2>FIIH;>)Y[B58X5%6=R%4 >9)H .@ZZB[\Z8[\Q^<RW2_9
M>T>S<5MK*C"9S)[/RL.9Q^/RK0"I2CDK:;532224S"12C,K(0P)!!]KMTV7=
MMEDBAW?;IK::1=:+,I4E:TK0YI7'1=M&^[+OT4T^R;I!=P1OX;O;N'4-0&A*
MDBM"#]AZ%WV6=&W7O?NO=%_[1^5OQHZ2S]#M3MSOCJKKG<V1BAJ*; ;MWM@<
M-F!25(D-/7U6.JZU*J@QL_B8)4SK' Q%@]^/9WMO+7,.\0O<[5LEU<6ZFA>&
M)V6OI4 @GY<>B#=>:N6=CGCMMYW^SM;AQJ6.XF1&(]:,P-/GPZ'#$Y;%9[&4
M&:P>3Q^9PV5I(*_&9;$UM-D<9D:&IC$M-64%?1R34M925$3!DDC=D=3<$CV3
MR1R0R/%+&RRJ:,K @@CB"#D'H\CDCE1)8G#1,*JRD$$'@01@@].'NG5^B^_)
MOY+];?$OJ?)=S=L#<']S<5EL+AJL[9Q469RHK,_6"@H#'0RUM KP_<, [>2Z
M@WL?9WR_L&X<S;G%M.UA#>.K,H=M(HHU'.?(=!_F?F;:^4=GN-]WEW7;XF57
M,:EB"[!5[1DY(ZK2_P"']/@7_7NG_P!%U1__ &4>Y _UE.>/]\VO_.4?YNHN
M_P""&]M?^4R[_P"<#]>_X?T^!?\ 7NG_ -%U1_\ V4>_?ZRG/'^^;7_G*/\
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MJ/U>))IT]><Q_>/L+2ZO[SZF.S@C::61K:RHJ(I9F/Z/ *">B??\/1?S+?\
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M:3LK<V26-"PLRFGR$;77B[$?4'VI]Y%*^X.\$\&2 C_G!&/\G2/V)8-[8[
M<J]P#_V42G_+U;;[B[J7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1K_ )Z.W:;"?S"M]U]/
M#2PMNS8/6.XJDTZ%'FJ8ML0;:::KNH5JIHMN(+BX,82YO?WF;[)W#3<B6T;,
M2(KF:,5\@6#T'RJY_.O6!_W@[:.W]Q)Y410TUG!*Q'F0&CJ?4T0#[ .K:O\
MA.7_ -D__(+_ ,3%B/\ WBL;[BSW_P#^5BV3_GB_ZROU,/W:?^54W[_I8_\
M6&+K8J]P+UD?U[W[KW1<^UOB'\7^\MR4N\>WNANK^PMUT=+3T,6X]S;2Q=?F
MI:"D<O24%;D6@6JR-!2,S>*"H:6*,.P50&8$^VSFCF/9K=K7:M[NK>V)+&.*
M1E6IXD &@)\R,\.@[NO*/*^^W*7F\\O6=U=JH42SQ([:020NH@DJ"30'&3Z]
M#SA<)AMMXC&[?V[B<9@,#A:&FQF'PF%H*7%XC$XVBB6"CQ^-QM#%!1T%#20(
MJ111(D<: !0 /9++++/+)-/(SS.2S.Y)8DY)).23Z]'T444$4<,$:I"BA41
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MXG>YN)[F3^TD=G;[6))_F>C.W@2VMX+:/^SC147[%  _D.E![9Z>Z*Y\XO\
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M2AG<J (B:,H>0@RR/2AIJ% 5[JB@C;DSD?GGW4M'YAYMYQO8MBG9E2)6-9@
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M?\\;G:[QN<$:7R6J6\ABJ%<HSG7I-=).K(J145% :#93_P"$Y?\ V3_\@O\
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M>^@?7,OKZ*_\OK_LAKXD?^*]=4_^\=BO> ///_*Y\U?]+"?_ *N-UTO]O/\
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M+:M52A!>E<:-?ATQHICJWV***"*.""..&&&-(H88D6.***-0D<<<: (D:(
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M=4CT(PRH5"D'@[8X=;<GO%KK,+KH@,"K $$$$$7!!X((/!!'OW7NOGR_S/\
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M7_9%7S _\5<^0'_OI]V^Q+R9_P KARG_ -+.U_ZOIT$^??\ E1N=/^E3>?\
M:/)U\XKWT#ZYE]?17_E]?]D-?$C_ ,5ZZI_]X[%>\ >>?^5SYJ_Z6$__ %<;
MKI?[>?\ *A\F_P#2KMO^K*='!]A7H8]>]^Z]U[W[KW6OQ_PHJ_[)1Z8_\6%Q
MO_OM^P_<Z>P7_*U;M_TKV_ZO0]8[?>5_Y4S9O^EHG_5B?JFW^1A_V\.Z[_\
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MYWO/+VX_Y47EC_GE7_">N<?NS_T\;FW_ )ZO^?%ZVV/Y(W_;N+I;_M?=M?\
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M6W=Z89X\9O/;)FU,PQ6:$,QEHFE;6]'5)444D@#-"7"L+*S*:@]>ZUQ_D_\
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M\^O=7K_R7O\ LCJH_P#$N[W_ /=9M;VQ-\?7NK:?;77NB.?S)_\ LA[Y"?\
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MBY-N6ZHW8JCG\DFP_P ?8EY,_P"5PY4_Z65K_P!7TZ"?/O\ RHO.G_2IN_\
MM'DZ^<7[Z!]<R^OHH_R\JF"J^"WQ)EIY5EC7H#K*F9DY GH]K8^DJHC]/5#4
MP.C?XJ?> 7/8*\Z<U C/U\Y_;(Q'\NNEWMV0W(7)I!Q^[+8?LB4'HX_L*=#+
MKWOW7NO>_=>ZU^/^%%7_ &2CTQ_XL+C?_?;]A^YT]@O^5JW;_I7M_P!7H>L=
MOO*_\J9LW_2T3_JQ/U3;_(P_[>'==_\ AC=I?^\;D/<L^]G_ "HEU_STP_\
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M=) I8D)&BK<DV]M=>Z=_?NO=% [>^!?Q/[XWQD.R.U^J?[U;TRE+CJ*OS/\
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M[*Y6L<:ZBLJY9JNID)>61V)/N*-RW3<-XO)=PW2\DGO'-6DD-3\@/( < !0
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M_N)_TT/_ %0MO^M/3/\ K'>UW_3+_P#9S=_];^O?\,N_RTO^\;/_ &,7?O\
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BKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
